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Phosphatome RNAi Screen Identifies Eya1 as a Positive Regulator of Hedgehog 
Signal Transduction  
Abstract 
 
The Hedgehog (Hh) signaling pathway is vital for vertebrate embryogenesis and 
aberrant activation of the pathway can cause tumorigenesis in humans.  In this study, we 
used a phosphatome RNAi screen for regulators of Hh signaling to identify a member of 
the Eyes Absent protein family, Eya1, as a positive regulator of Hh signal transduction.  
Eya1 is both a phosphatase and transcriptional regulator.  Eya family members have been 
implicated in tumor biology, and Eya1 is highly expressed in a particular subtype of 
medulloblastoma (MB).  Here we show that RNAi-mediated knock-down of Eya1, as 
well as knock-down of its co-factor, Six1, blocks Hh signaling as assessed by induction 
of Hh response genes.  Utilizing small molecule agonists, RNAi, and protein over-
expression methods, we place the influence of Eya1 and Six1 within the Hh signaling 
pathway downstream of Smoothened (Smo) and at or above the level of Suppressor of 
Fused (Sufu).  Interestingly, Eya1 appears to be specifically required for Hh-responsive 
gene activation mediated by Gli transcriptional activators but not for Hh-mediated 
transcriptional de-repression mediated by the inhibition of Gli transcriptional repressors.  
Furthermore, we find that Eya1 and Six1 regulate the expression of Neuropilin1 (Nrp1) 
  
iv 
and Neuropilin2 (Nrp2), known positive regulators of Hh signaling, providing a 
mechanism by which Eya1 and Six1 exert their effects. 
Based on these data, we investigated a role of Eya1 in Hh signaling in vivo.  We 
obtained Eya1
-/-
 mice and focused our attention on the developing cerebellum, where 
Sonic Hedgehog (Shh) is a major factor promoting neural precursor proliferation. In the 
Eya1
-/-
 cerebellum, we find a striking reduction in neural precursor proliferation.  In 
addition, we surveyed several other locations where Shh and/or Eya1 are known to be 
important for development.  These include the embryonic otic vesicle, neural tube, and 
lung.  In the developing inner ear we find Eya1
-/-
 mice display reduced Hh signaling in 
vivo and a genetic interaction between Eya1 and Hh signaling.  In lung tissue, Eya1
-/-
 
mice have reduced levels of Nrp expression.  Together, these data further our 
understanding of the Hh signaling pathway and provide evidence for a role of Eya1 in Hh 
signal transduction.
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CHAPTER 1: INTRODUCTION 
Hh Signaling: In Flies and Mice 
Hh was first identified in the fruit fly Drosophila melanogaster (Drosophila) and 
was named for its role in embryonic patterning, as mutants exhibit a pattern of larval 
denticles that resemble the bristles of a hedgehog (Nusslein-Volhard & Wieschaus, 
1980).  In Drosophila, Hh signaling is important for embryonic segmental identity and 
for the development of imaginal discs that give rise to adult structures such as the wing 
and eye imaginal discs (reviewed in Hooper et al. 2005).  Subsequently, three mammalian 
homologs have been identified, Indian Hedgehog (Ihh), Desert Hedgehog (Dhh), and Shh 
(reviewed in Ingham & McMahon 2001).  Ihh functions primarily in bone development, 
Dhh is present in the peripheral nervous system and is involved in reproductive organ 
development, while Shh is a key regulator in many areas of development including the 
development of the nervous system (Chiang et al. 1996), limb (Chiang et al. 2001; 
Bénazet & Zeller 2009), lung (Pepicelli et al. 1998), and kidney (Yu et al. 2002).  In these 
tissues, Shh acts as a mitogen and/or morphogen.  Additionally, dysregulated Shh 
signaling can result in a wide variety of devastating birth defects (reviewed in Cohen 
2010) and the development of cancers (reviewed in Barakat et al. 2010).  This chapter 
will discuss Hh signal transduction in Drosophila and vertebrates. 
The basic principles of Hh signal transduction as initially characterized in 
Drosophila are largely evolutionarily conserved.  Many of the underlying molecular 
mechanisms, however, have diverged from flies to mice, including the appearance of the 
primary cilia in vertebrate Hh signaling (reviewed in Robbins et al. 2012; Ingham et al. 
2011; Wilson & Chuang 2010). 
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Hh Ligand Production 
In Drosophila and vertebrates, Hh is a signaling molecule secreted into 
extracellular space, able to signal to cells near and far.  It is synthesized as a precursor 
and undergoes multiple post-translational modifications before release.  The 45kDa Hh 
precursor peptide is targeted to the endoplasmic reticulum and the Golgi apparatus, where 
it undergoes autoproteolytic cleavage, generating two fragments, a 19kDa N-terminal 
fragment with a cholesterol attached to its C-terminus and a 25kDa C-terminal fragment, 
(Lee et al. 1994; Bumcrot et al. 1995; Porter et al. 1996).  The N-terminal fragment then 
receives a palmitate to its N-terminus via the acyltransferase Skinny hedgehog (Ski/Skn), 
generating a signaling molecule with two permanent lipid attachments (Chamoun et al. 
2001; Pepinsky et al. 1998).  The dually-lipidated N-fragment (referred to as “Hh” from 
here on) forms multimers, is packaged into lipoprotein particles, and is released into 
extracellular space with the help of Dispatched (Disp/Displ1), a 12-pass transmembrane 
protein (Zeng et al. 2001; Burke et al. 1999; Caspary et al. 2002; Kawakami et al. 2002).  
Hh’s dual modifications are important for high-level Hh signaling, multimerization 
and/or packaging (Zeng et al. 2001; Chen et al. 2004a), movement in extracellular space, 
and gradient distribution (Li et al. 2006).   
Hh Ligand Reception 
In both Drosophila and mammalian Hh-responding cells, Hh signaling is 
transduced as described below (see Figure 1.1a-b for a representation of mammalian Hh 
signal transduction).   
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Figure 1. 1 Vertebrate Hh signal transduction 
 
Figure 1.1 Vertebrate Hh signal transduction. A) In the absence of Hh ligand, 
Ptch1 localizes to the primary cilia and inhibits Smo activation. Full-length Gli 
complexes with Sufu in the cytoplasm.  Sufu and Kif7 promote the phosphorylation of 
Gli by PKA, GSK3β, and CK1α. Phosphorylated Gli is recognized by the E3 ubiquitin 
ligase βTrCP, resulting in ubiquitination and proteasomal degradation to generate an 
N-terminal Gli repressor, GliR. B) In the presence of Hh ligand, Ptch1 exits the cilia 
allowing Smo transport into the cilia. Active Smo promotes the ciliary localization 
and the disassembly of Sufu, Gli, and Kif7. Full-length Gli is shuttled from the cilia 
into the nucleus where it activates Hh target genes.  Adapted from (Ryan & Chiang 
2012). 
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Hh binds its receptor Patched (Ptc/Ptch1), a twelve-pass transmembrane protein 
and negative regulator of pathway activity.  In the absence of Hh ligand binding, Ptch1 
inhibits the activity of Smo, a seven-pass transmembrane protein and potent pathway 
activator.  The mechanism by which Ptch1 inhibits Smo is an open question.  Given 
sequence similarities between Ptch1 and the RND family of bacterial transporter proteins, 
it is thought Ptch1 represses Smo by regulating the transport and/or synthesis of an 
unidentified small molecule (Taipale et al. 2002).  Upon Hh binding, Ptch1 repression of 
Smo is relieved and Smo is activated.   
Hh binding to Ptch1 is affected by the presence of other Hh-binding proteins at 
the cell surface (Figure 1.1b).  Positive regulators of Hh reception include the co-
receptors Ihog/Cdo, Boi/Boc, and the vertebrate specific Gas1 (reviewed in Beachy et al. 
2012).  A second vertebrate specific Hh-binding protein, Hhip, acts as a negative 
regulator of Shh signaling, likely by competing with Ptch1 for available Hh ligands 
(Chuang & McMahon 1999).  Interestingly, these Hh-binding proteins are 
transcriptionally regulated by Hh signaling, thereby introducing a number of negative 
feedback loops that function to attenuate signaling.  Positive co-receptors (i.e., Ihog/Cdo, 
Boi/Boc, and Gas1) are transcriptionally repressed while the expression of negative co-
factors (i.e., Ptch1 and Hhip) is up-regulated following pathway activation.  These 
complex negative feedback loops may function to sensitize and/or desensitize cells to Hh 
signaling and is crucial for cells to properly interpret the duration and graded level of Shh  
Signaling they receive (reviewed in Ribes & Briscoe 2009).  
In both Drosophila and mammalian Hh signaling, the reciprocal trafficking and 
subcellular localization of Ptch1 and Smo are important.  In both systems, Ptch1 and Smo 
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are found in opposite locations.  The manner in which the proteins are localized and 
regulated, however, is a point of divergence between the two systems.  In Drosophila, 
inactivated Smo is retained intracellularly in endosomes and vesicles.  Ptc is present at 
the plasma membrane and in intracellular compartments and prevents Smo localization at 
cell surface.  Upon Hh binding, Ptc and Hh form complexes which are internalized and 
degraded, allowing Smo movement to the cell surface where it is active (Denef et al. 
2000; Zhu et al. 2003).   
In the mammalian system, the trafficking of Ptch1 and Smo involves the primary 
cilia, a microtubule-based organelle present on nearly all mammalian cells (Figure 1.1a-
b).  In the absence of Hh binding, Ptch1 is localized to the cilia and Smo is not; upon Hh 
binding, Ptch1 moves from the cilia and Smo translocates to the cilia (Corbit et al. 2005; 
Rohatgi et al. 2007).  Smo translocation to the cilia is dependent on Kif3a and β-arrestin2 
(β-Arr; Chen et al. 2004b; Kovacs et al. 2008).   
Although the details are yet to be fully elucidated, the biochemical activation of 
Smo diverges from flies to mice.  In Drosophila, Smo is hyperphosphorylated at its C-
terminal tail by protein kinase A (PKA) and casein kinase I (CK1α), translocates to the 
cell membrane, and undergoes conformational changes (reviewed in Chen & Jiang 2013).  
The phosphorylation of Smo is critical for its activation; the extent of phosphorylation 
corresponds to its activity level and to the amount of Smo accumulated at the cell surface 
(Jia et al. 2004; Zhang et al. 2004a).  The C-terminus of mammalian Smo does not 
contain PKA phosphorylation sites although phosphorylation may still be an important 
regulatory mechanism (Chen et al. 2011b).  Mammalian Smo is phosphorylated in 
response to Hh signaling by G-protein coupled receptor kinase 2 (GRK2) and CK1α, 
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inducing a conformational change and transport into the primary cilia (Chen et al. 
2011b). 
Gli Transcription Factors 
The Gli family transcription factors (Ci/Gli) are conserved as the effectors of Hh 
signaling.  Ci/Gli can serve as transcriptional repressors (CiR/GliR) or activators 
(CiA/GliA) and thereby mediate Hh signaling (Méthot & Basler, 2001).  Hh signaling 
induces gene transcription by two mechanisms: de-repression of transcription by blocking 
CiR/GliR function and direct transcriptional activation through promoting CiA/GliA 
function (reviewed in Hui & Angers 2011).  Low levels of Hh signaling block CiR/GliR, 
while higher levels of Hh are needed to activate CiA/GliA (Méthot & Basler 2000).  In 
accordance with this model, graded Hh signaling triggers the expression of different sets 
of response genes by shifting the balance of GliR relative to GliA (reviewed in Hui & 
Angers 2011; Ribes & Briscoe 2009) 
The repressor and activator functions of Ci have been distributed among three 
vertebrate homologs, Gli1-3.  Gli3 serves as the primary transcriptional repressor of the 
pathway, Gli2 is primarily a transcriptional activator, and Gli1 exists only as a 
transcriptional activator.  Gli1 is a Shh response gene, acting as positive feedback to 
strengthen GliA activity and serves as a readout of pathway activation.  For Ci/Gli2/3, the 
Hh-induced switch between repressor and activator functions is regulated through 
phosphorylation.   
In the absence of Hh signaling, full-length Ci/Gli proteins are constitutively 
phosphorylated at multiple phosphorylation sites by PKA, CK1α, and glycogen synthase 
kinase 3 (GSK3; Figure 1.1a; Chen et al. 1998; Price & Kalderon 1999; Price & Kalderon 
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2002; Jia et al. 2002; Pan et al. 2006; Pan et al. 2009; Tempé et al. 2006).  The newly 
hyperphosphorylated Ci/Gli is recognized by Slimb/βTrCP, a substrate-specific receptor 
of an E3 ubiquitin ligase, ubiquitinated and targeted for proteosomal processing (Jiang & 
Struhl 1998; Tempé et al. 2006; Pan et al. 2006; Wang & Li 2006).  The resulting 
truncated peptide acts as a transcriptional repressor.  Full-length Gli2 and full-length Gli3 
are both phosphorylated but Gli3 is processed more efficiently and proteolyzed to form 
Gli3R while the majority of Gli2 remains full-length.  Gli2 that is phosphorylated and 
processed is degraded by the proteosome (Pan & Wang 2007; Pan et al. 2006).  The 
preferential formation of Gli3R over Gli2R may be due to a difference in the C-terminal 
domains of proteins (Pan & Wang 2007; Pan et al. 2006). 
Upon Smo activation, Ci/Gli proteolysis is inhibited.  Simultaneously, the 
activator function of full-length Ci/Gli proteins is promoted (see below).  It is unclear 
why Gli2 preferentially acts as an activator.  One hypothesis is that full-length Gli3 is 
more efficiently degraded than Gli2 in the nucleus via the Cullin-3-based ubiquitin ligase 
adaptor HIB/Spop (Chen et al. 2009; Wen et al. 2010).  Gli1 is not degraded by Spop 
(Chen et al. 2009; Wen et al. 2010).   
In addition to PKA, CK1α, and GSK3 phosphorylation control of Gli processing, 
other kinases influence the activity of Gli proteins in mammalian cells.  Dual-specificity 
tyrosine phosphorylation-regulated kinase 1A (DYRK1A) phosphorylates Gli1 
promoting nuclear localization and transcriptional activity of GFP-tagged Gli1 (Mao et 
al. 2002).  DYRK1B acts as a negative regulator of transcriptional output by inhibiting 
Gli2A (Lauth et al. 2010).  In addition, DYRK2 phosphorylates Gli2 and promotes 
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proteosomal degradation of Gli2-3 (Varjosalo et al. 2008).  MAP3K10  affects Gli2 
indirectly by modulating the activity of DYRK2 and GSK3 (Varjosalo et al. 2008).  
Hh Signal Transduction 
The composition, formation, and assembly of intracellular signaling complexes 
controlling Ci/Gli activity exhibit great evolutionary divergence.  In Drosophila, Ci is 
found in a complex with Costal2 (Cos2), Fused (Fu), and Sufu proteins (reviewed in 
Wilson & Chuang 2010; Hooper & Scott 2005).  In the absence of Hh, Cos2 functions 
primarily as a negative regulator of signaling.  Cos2 associates with microtubules and 
serves as a scaffold for PKA, CKI and GSK3 to promote the efficient phosphorylation of 
Ci and subsequent formation off CiR.  Upon activation, Smo binds Cos2 and Fu 
phosphorylates Cos2 leading to the dissociation of complex and blunting of CiR 
production.  Sufu may serve as a negative regulator of the pathway by associating with Ci 
to keep it from going into the nucleus and becoming an activator.  Sufu’s primary role in 
the Drosophila Hh pathway, however, seems to be regulating Ci stability by blocking 
HIB/Spop-mediated degradation (Chen et al. 2009).  
Targeted knockout studies in mice have shown a conserved role for the Cos2 
homolog, Kif7, where it may play an analogous scaffolding role localizing components of 
the pathway to the primary cilia (Cheung et al. 2009; Endoh-Yamagami et al. 2009; Liem 
et al. 2009).  Kif7 localizes at the base of the cilia near the basal body and interacts with 
Gli proteins (Figure 1.1a).  Kif7
-/-
 have spinal cord and limb phenotypes consistent with 
loss of Gli3R function showing Kif7 is needed for the formation of GliR.  When crossed 
onto Gli2
-/-
 and Ptch1
-/-
 backgrounds, Kif7
-/-
 double-mutant phenotypes suggest Kif7 also 
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has a positive regulatory role, perhaps by regulating Gli2 localization (Cheung et al. 
2009; Endoh-Yamagami et al. 2009; Liem et al. 2009).   
In contrast, the targeted knockout of the mouse Fu homolog has no Hh-related 
phenotypes, suggesting the role of this kinase is not conserved (Merchant et al. 2005; 
Chen et al. 2005).  In vertebrate Hh signaling, Sufu plays new and more significant roles.  
In mammalian Hh signaling, Sufu regulates Glis at several distinct steps, serving as a 
potent inhibitor of the pathway.  Sufu knock-down in NIH3T3 cells and Sufu
-/-
 mouse 
embryonic fibroblasts display ligand-independent pathway activation (Svärd et al. 2006; 
Cooper et al. 2005; Varjosalo et al. 2006).  Sufu
-/-
 embryos die by embryonic day 9.5 
(E9.5) resembling the gain-of-function phenotype found in Ptch1
-/-
 embryos (Svärd et al. 
2006; Cooper et al. 2005). 
Sufu directly interacts with all three Gli proteins in the absence of Hh signaling 
and sequesters full length Gli in the cytoplasm (Figure 1.1a).  This sequestration has two 
effects: it promotes the phosphorylation of full-length Gli and thus GliR formation 
(Humke et al. 2010) while preventing nuclear translocation and inappropriate pathway 
activation (Ding et al. 1999; Kogerman et al. 1999).  Cytoplasmic Sufu and Gli dissociate 
upon Hh binding (Figure 1.1b; see below).  As in Drosophila, mammalian Sufu stabilizes 
full-length Gli2 and Gli3 by protecting them from proteosomal degradation mediated by 
Spop/Cul3 in the nucleus (Wang et al. 2010).  In this role, Sufu functions as a positive 
regulator in Hh signaling transduction.  Sufu phosphorylation by Cdc2l1 modulates Sufu-
Gli binding and relieves Sufu inhibition of Gli-dependent transcription (Evangelista et al. 
2008).  Sufu function can also be modulated by phosphorylation.  PKA- and GSK3-
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mediated phosphorylation promotes Sufu ciliary localization and thereby negatively 
regulates Shh signaling (Chen et al. 2011a). 
Primary Cilia 
The primary cilia functions as a signaling center to facilitate Hh signal detection 
and pathway activation.  Many of the core components of the vertebrate Hh pathway 
localize to cilia and pathway activation requires the primary cilia.  The primary cilia is a 
microtubule-based structure consisting of an axoneme, nine peripheral double tubules 
arranged around a core (reviewed in Goetz & Anderson 2010).  The assembly, 
disassembly, and maintenance of the cilia depend on intraflagellar transport (IFT) 
proteins and their associated kinesin and dynein motors. Mice lacking cilia due to 
mutations in critical IFT genes display a loss of GliR and GliA function, demonstrating a 
requirement of cilia for proper Hh signal transduction and Gli processing (Houde et al. 
2006; Huangfu et al. 2003; Liu et al. 2005; May et al. 2005; Tran et al. 2008). 
Many critical core components of Hh signaling localize to the cilia in a Hh-
dependent manner, including Ptch1, Smo (Rohatgi et al. 2007), Kif7 (Endoh-Yamagami 
et al. 2009), and Gli proteins.  Upon pathway activation, Sufu-Gli complexes move into 
the cilia and dissociate, allowing Gli to accumulate at the distal tip of the cilia and also 
translocate to the nucleus and activate gene transcription (Figure 1.1b; Humke et al. 
2010; Tukachinsky et al. 2010; Chen et al. 2009; Wen et al. 2010; Kim et al. 2009).  The 
activation of endogenous GliA correlates with ciliary accumulation; prompting the 
hypothesis that GliA formation is regulated via transport or accumulation in the cilia 
(Wen et al. 2010; Qin et al. 2011; Tran et al. 2008).   
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Hh Activation in Tumorigenesis 
 Many human cancers have active Shh signaling as indicated by GIL1 and PTCH1 
expression, including MB, basal cell carcinoma (BCC), glioma, gastrointestinal cancer, 
leukemia, breast cancer, and prostate cancer (reviewed in Marini et al. 2011).  The 
identification of PTCH1 mutations in Gorlin syndrome patients, who develop multiple 
BCCs and have increased risk of MB, provided the first clues that activation of the 
canonical Hh signaling pathway is sufficient to initiate tumorigenesis (Hahn et al. 1996; 
Johnson et al. 1996).  The ability of Hh signaling to cause cancer has subsequently been 
confirmed in mouse models and inhibition of the pathway provides a novel successful 
treatment for some cancers (see below). 
MB is a highly malignant brain tumor of cerebellar origin and is the most 
common malignant brain tumor in children.  Current treatments for MB include surgery, 
craniospinal radiation and chemotherapy, which can result in severe long-term side-
effects in young patients (reviewed in Leary & Olson 2012).  Thus, developing targeted 
drug therapies limiting the dose of radiation therapy is of great interest.   
There are multiple subtypes of MB defined by distinctive gene expression profiles 
and tumor histologies.  About 25% of MBs belong to the “Shh-subtype”, which is 
characterized by aberrant expression of Shh pathway components and increased Shh 
pathway activation (reviewed in Northcott et al. 2012).  The ability of Hh signaling to 
initiate MB is consistent the role of Shh as a mitogen in cerebellar development 
(reviewed in Manoranjan et al. 2012).  Aberrant activation of the Hh pathway has been 
shown to generate MB via any one of multiple mechanisms: by loss-of-function of 
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negative pathway regulators Ptch1 and Sufu, and over-active mutations of Smo or Gli2 
(Lee et al. 2009; Hatton et al. 2008).   
BCC, the most common cancer in humans, is a skin cancer thought to arise from 
the abnormal proliferation of cells that normally form the hair follicle (reviewed in 
Barakat et al. 2010; Epstein et al. 2008).  Most sporadic BCCs have activated Hh 
signaling (Reifenberger et al. 2005).  Specifically, 90% of sporadic BCC patients have 
mutations in at least one PTCH1 allele and an additional 10% have SMO activating 
mutations, with less frequent SUFU mutations.  In mice, loss of Ptch1, loss of Sufu, 
active Smo, or active Gli can result in BCC (reviewed in Barakat et al. 2010). 
Several promising small molecule inhibitors of the Smo have been developed and 
are in clinical trial to treat BCC and MB (reviewed in Cohen et al. 2012).  Vismodegib 
(GDC-0449; Curis/Genentech), recently became the first FDA approved Hh pathway 
inhibitor, approved for the treatment of BCC; clinical trials for the treatment of other 
cancers with active Hh signaling are underway.  
Studies in the past twenty years have provided many insights into the mechanisms 
of Hh pathway signaling, including the importance of subcellular localization and protein 
phosphorylation as regulatory mechanisms.  Future studies to identify additional Hh 
pathway targets and inhibitors will be important to treat tumors which are caused by 
mutations downstream of Smo and to treat patients who develop resistance to Smo 
inhibitors through acquired SMO mutations (Rudin et al. 2009; Yauch et al. 2009).  Two 
low-molecular-weight compounds inhibiting Gli function, GANT58 and GANT61, have 
been identified (Lauth et al. 2007).  A more detailed understanding of Hh pathway 
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components downstream of Smo and of the mechanisms that regulate these components 
could offer further therapeutic targets and expand the treatable patient population. 
The Retinal Determination Gene Network (RDGN) 
In Drosophila, eye development is controlled by members of the RDGN, Ey, Toy, 
Eya, So, and Dac (Figure 1.2; reviewed in Rebay et al. 2005; Pappu & Mardon 2004).  
These transcription factors and co-factors form protein complexes to control gene 
expression.  Members of the RDGN are necessary for eye development and, with the 
exception of So, their overexpression is sufficient to induce ectopic eye development in 
Drosophila.  The RDGN is hierarchical with Ey and Toy inducing the expression of So 
and Eya. 
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Figure 1. 2 The RDGN 
 
Figure 1.2 The RDGN. In Drosophila eye development, the RDGN is expressed in a 
transcriptional hierarchy in which Toy/Pax6 promotes Ey/Pax6 expression, which 
leads to the expression of So/Six1-2 and Eya/Eya1-4.  In Drosophila eye 
development, So/Six1-2 and Eya/Eya1-4 interact with Dac/Dach1-2.  Feedback loops 
maintain Ey/Pax6 expression.  This network is adapted to vertebrate development.  
Solid arrows represent known transcriptional relationships; dotted-arrows represent 
known protein-protein interactions.  Drosophila gene names are on the left, vertebrate 
homologs are on the right.  Adapted from (Jemc & Rebay 2007). 
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RDGN members are conserved in mammals: Pax6 is a homolog of Ey and Toy, 
Eya1-4 are Eya homologs, Six1-2 are So homologs, and there are two vertebrate Dac 
proteins, Dach1-2.  In mammalian development, this network plays roles in the 
development of multiple organs including the eye, muscle, ears, lungs, and craniofacial 
skeleton (reviewed in Tadjuidje & Hegde 2012).   
Six family proteins are homeodomain-containing factors characterized by a highly 
conserved Six domain.  There are three subgroups within this family: So/Six1-2, 
dSix4/Six4-5, and Optix/Six3/6 (Jean et al. 1999; Seo et al 1999).  Six transcription 
factors are repressors or weak activators.  However, co-transcriptional binding partners 
can result in repressor or activator functions.  For example, Six1-2 bind Groucho family 
co-repressors (Lopez-Rios et al. 2003; Kobayashi et al. 2001) while binding to Eya 
converts Six1-2 and Six4-5 into strong transcriptional activators (Ohto et al. 1999; Li et 
al. 2003).  Unlike Six1-2 and Six4-5, Six3/6 have not been shown to interact with Eya. 
Eya1 
The human EYA1 gene was first identified in patients with branchio-oto-renal 
(BOR) or branchio-oto (BO) syndromes (Abdelhak et al. 1997).  BOR patients are born 
with ear, kidney, and lung defects (reviewed in Kochhar et al. 2007).  93% of affected 
individuals are deaf and BOR accounts for 2% of profoundly deaf children (Abdelhak et 
al. 1997).  Mutations in EYA1 account for 40% of BOR patients; SIX1 and SIX5 
mutations are also found in BOR patients (Ruf et al. 2004; Hoskins et al. 2007).  In mice, 
Eya1 null mutations result in lethality at birth, failure of inner ear development, 
dysmorphic or absent kidneys, lung abnormalities, craniofacial and skeletal defects, as 
well as thymus, parathyroid, and thyroid defects (Xu et al. 1999; Xu et al. 2002; El-
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Hashash et al. 2011b).  While EYA1 mutations have been identified in human patients 
with congenital cataracts and other ocular abnormalities (Azuma et al. 2000), Eya1
-/-
 
mice do not have an eye phenotype, suggesting the crucial role of Eya in eye 
development is not conserved from flies to vertebrates.  However, multiple Eya genes are 
expressed in the murine eye, leaving open the possibility that there is functional 
redundancy among multiple Eya family members in the developing eye (Xu et al. 1999). 
Eya as a Transcription Factor  
As a member of the RDGN, Eya proteins are co-transcriptional activators.  Eya 
does not have the ability to bind DNA directly and activates gene transcription through 
protein-protein interactions with Six or Dach transcription factors (reviewed in Tadjuidje 
& Hegde 2012; Jemc & Rebay 2007).  Eya proteins have a highly conserved C-terminal 
domain called the Eya domain (ED) and an N-terminal domain that is less well 
conserved.  The ED domain is necessary for Eya to bind Six or Dach proteins (Ohto et al. 
1999; Li et al. 2003) and the N-terminal domain contains a proline/serine/threonine rich 
region required for transactivation (Xu et al. 1997; Silver et al. 2003).  In vitro, 
overexpressed Eya is cytoplasmic.  When co-transfected with Six1-2 or Six4-5, Eya and 
Six proteins form complexes and translocate to the nucleus (Ohto et al. 1999; Zhang et al. 
2004b).  Eya and Dac are thought to bind directly in Drosophila eye development but a 
direct interaction between vertebrate Eya and Dach proteins is less well established.  Eya 
is not known to have a Six- or Dach-independent ability to activate gene transcription. 
Eya as a Phosphatase  
  Eya1 is a rare example of a transcription co-factor that is also a phosphatase 
(Rebay et al. 2005).  The ED domain contains sequence motifs that match haloacid 
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dehalogenase (HAD) class of enzymes and has active tyrosine phosphatase activity (Li et 
al. 2003; Tootle et al. 2003; Rayapureddi et al. 2003).  In addition, the N-terminal domain 
appears to have activity as a threonine phosphatase (Okabe et al. 2009, Sano & Nagata 
2011).  Eya is not considered a dual specificity phosphatase, however, because its 
phosphatase activities are in different catalytic domains and there is no evidence that Eya 
can dephosphorylate tyrosine and threonine residues of the same substrate. 
 The dual activities of Eya, as a transcription co-factor and as a phosphatase, raise 
the question as to whether and how these functions are linked.  The discovery that Eya 
dephosphorylates the histone H2A variant H2AX in the nucleus following double-
stranded DNA breakage suggests that Eya acts as a phosphatase independently of its role 
as a co-transcriptional factor (Cook et al. 2009; Krishnan et al. 2009).  Eya also interacts 
with cytoplasmic Abelson (Abl) tyrosine kinase in the Drosophila larval visual system 
(Xiong et al. 2009).  Abl phosphorylates Eya which recruits Eya to the cell membrane 
where Eya function requires phosphatase activity.  These data suggest Eya has 
cytoplasmic roles as a phosphatase in development that are independent of its nuclear 
functions (Xiong et al. 2009).  
It is possible that Eya phosphatase activity is also important for its role as a 
transcriptional co-factor.  Missense mutations that ablate Eya tyrosine phosphatase 
activity without impairing Eya protein-protein interactions show reduced transactivation 
activity, compromise the ability of full-length Eya to rescue the eyeless phenotype in 
Drosophila, and do not induce eye formation as effectively in vivo in Drosophila 
(Rayapureddi et al. 2003; Tootle et al. 2003).  These data demonstrate that Eya 
phosphatase activity is not required for but contributes to Eya transcriptional activity.  
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Human BOR mutations appear to disrupt both the phosphatase activity and 
transactivation functions of Eya without affecting the ability of Eya to translocate to the 
nucleus with Six (Buller et al. 2001).  Similarly, in vitro studies in cultured Drosophila 
cells indicate that Eya-Six interactions are not compromised with HAD- or BOR-type 
mutations (Mutsuddi et al. 2005).  Together, these studies suggest phosphatase-dead Eya 
binds to Six but the complex is impaired in their ability to activate transcription.  How, 
exactly, Eya phosphatase activity influences transcriptional regulation remains unclear.  
Cellular Functions of Eya 
 H2AX is a physiologically relevant Eya substrate (Krishnan et al. 2009; Cook et 
al. 2009).  Following double-stranded DNA breaks, H2AX is phosphorylated at Ser139 
near the breakage to produce a modified form, termed γH2AX (reviewed in Stucki 2009).  
γH2AX is recognized by MDC1, a large protein which coordinates the assembly of DNA 
damage response proteins.  H2AX is constitutively phosphorylated at Tyr142 and, in 
contrast to Ser139, this residue is dephosphorylated following double-stranded breaks in 
a manner that is dependent on Eya1 or Eya3 (Cook et al. 2009).  Eya1 and Eya3 interact 
with γH2AX and loss of Eya1 or Eya3 results in increased cell death in vivo.  It seems 
MDC1 more stably associates with γH2AX after Tyr142 dephosphorylation (Cook et al. 
2009; Xiao et al. 2009).  In this way, Eya-mediated dephosphorylation of H2AX Ty142 
promotes DNA repair and cell survival over apoptosis (Figure 1.3; Stucki 2009).  
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Figure 1. 3 Eya promotes cell survival following DNA double-stranded breakage  
 
 Figure 1.3 Eya promotes cell survival following DNA double-stranded breakage.  
H2AX (blue circle) is constitutively phosphorylated at Tyr142 by WSTF (Williams–
Beuren syndrome transcription factor, also known as BAZ1B).  Upon double-stranded 
DNA breakage (indicated by a yellow star), H2AX is phosphorylated at Ser139 by the 
ATM (ataxia-telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related 
protein) kinases.  Eya dephosphorylates H2AX Tyr142, facilitating the recruitment of 
MDC1 (mediator of DNA damage checkpoint 1) and cell survival.  If H2AX remains 
dually-phosphorylated, JNK1 (c-Jun N-terminal protein kinase 1) is recruited, leading 
to apoptosis. 
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In addition to the better characterized roles of Eya described above, Eya has been 
implicated in a variety of other cellular functions.  In both Drosophila (Bai & Montell 
2002) and vertebrates Eya plays a role regulating tissue polarity (El-Hashash et al. 
2011a).  In vertebrates Eya1 is involved in controlling mitotic spindle orientation in lung 
epithelium through dephosphorylation of aPKC-zeta and Numb (El-Hashash et al. 
2011a).  In addition, Eya4 has been implicated in regulating the innate immune response 
to nuclei acids in vitro via interactions with IPS-1, Sting, Nlrx1 (Okabe et al. 2009).  This 
response requires Eya4 N-terminal threonine phosphatase activity (Okabe et al. 2009).  
Eya1 has been shown to interact with Sox2 by immunoprecipitation and may have a role 
in sensory cell development of the inner ear (Zou et al. 2008).  Eya2 appears to bind Gαz 
and Gαi subunits which recruit Eya to the cell membrane and prevent Six-mediated 
nuclear translocation (Embry et al. 2004; Fan et al. 2000).  Finally, Eyas are implicated in 
cell migration, a function fundamental to developmental biology with important 
implications for cancer biology.  Overexpression of Eyas in breast epithelial cell lines 
increases cell migration (Stucki 2009; Tadjuidje et al. 2012) while RNAi targeting Eya3 
or Eya4 reduce migration in endothelial cells or malignant peripheral nerve sheath tumor 
cells, respectively (Tadjuidje et al. 2012; Miller et al. 2010).   
Eyas are unusual proteins as they contain both phosphatase and transactivation 
functions.  Eyas are required for the normal development of many organs and Eya 
mutations result in multiple disorders.  Future studies identifying mechanisms regulating 
Eya activity, additional Eya substrates, and additional Eya binding partners will be of 
great interest.   
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In the following study, we conduct an RNAi screen with the aim of identifying 
novel phosphatases regulating the Hh signaling pathway.  We apply a phosphatome 
library of shRNAs to Hh-responsive cells and identify Eya1 as a factor needed for 
maximal hedgehog signaling in Hh-responsive cells.  We find evidence that Eya1 is 
working in concert with its co-factor Six1 to regulate gene expression necessary for Hh 
signaling transduction.  Specifically, we find Eya1 and Six1 regulate Nrp expression, a 
known regulator of Hh signaling (Hillman et al. 2011), thus providing a mechanism 
underlying the requirement of Shh signaling for Eya1 and Six1.  Furthermore, we present 
data in the developing mouse demonstrating in vivo significance for this interaction. 
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CHAPTER 2: IDENTIFICATION OF NOVEL 
PHOSPHATASES IN THE HH SIGNALING PATHWAY BY 
RNAi SCREENING 
Introduction  
The history of Hh signaling is closely tied to screening in that Hh itself was 
identified in a Drosophila mutagenesis screen as an important determinant of segmental 
patterning in larva (Nusslein-Volhard & Wieschaus 1980).  Subsequent screening has 
proven successful in identifying novel signaling components of the Hh pathway via 
mutagenesis screens, RNA interference (RNAi) screens, and protein overexpression 
screens in Drosophila and mammalian Hh signaling pathways (Nusslein-Volhard & 
Wieschaus 1980; Lum et al. 2003; Nybakken et al. 2005; Varjosalo et al. 2008; 
Evangelista et al. 2008; Hillman et al. 2011; Jacob et al. 2011).  Non-overlapping sets of 
hits between screens to identify components of the Hh pathway, however, suggest that 
little can be conclusively said for genes that are not selected as hits in a study and that 
these screens were not saturated and are complementary (Evangelista et al. 2008; 
Varjosalo et al. 2008).  Given the success of previously published screens and the fact 
that much remains to be discovered about this important pathway, we were motivated to 
further screen for novel regulators of Hh signaling by RNAi. 
In contrast to hypothesis testing, unbiased screening allows investigators to look 
beyond the current understanding of biology and releases scientists from the constraint of 
preconceived ideas.  Over decades, screens have yielded seminal discoveries and opened 
new areas of study.  In addition to classical in vivo mutagenesis screens, the discovery of 
RNAi has provided an additional approach to screening whereby an investigator is able to 
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selectively deplete particular gene products.  Unlike in vivo mutagenesis screens, by 
screening with an RNAi library (i.e., genome-wide RNAi or RNAi targeting each of a 
specific class of gene products), an investigator can systematically test the significance of 
individual genes within a biological system.  This approach also allows an investigator to 
examine the effect of acutely depleting a gene product and avoids costly and time 
consuming gene mapping.  In addition, this approach is free from limitations of 
selectivity imposed by mutagenesis methods. 
There are multiple methods to achieve RNAi-mediated knock-down of a specific 
gene product (reviewed in Campeau & Gobeil 2011; Echeverri & Perrimon 2006), many 
of which have been utilized in RNAi screens designed to identify components of Hh 
signaling (Lum et al. 2003; Nybakken et al. 2005; Jacob et al. 2011; Hillman et al. 2011; 
Evangelista et al. 2008).  Drosophila cells can be treated with double-stranded RNA 
(dsRNA), which are processed by Dicer into small interfering RNAs (siRNA).  siRNAs 
range from 19 to 27 nucleotides and are incorporated into the RISC silencing complex, 
resulting in sequence-specific degradation of messenger RNAs (mRNAs).  In mammalian 
cells, siRNAs may be generated by treating long dsRNA with recombinant Dicer enzyme 
in vitro to generate diced RNAi pools or they may be synthesized and introduced by 
lipid-based transient transfection.  Vector-expressed short hairpin RNAs (shRNAs) can 
be introduced via viral particles and are stably incorporated into the cell’s genome.  
shRNAs are about 65 nucleotides long and are cleaved by the Dicer complex to generate 
siRNAs. 
Differences in sets of hits could be due to different experimental RNAi screening 
setups and/or methods of statistical analyses and hit criteria (Campeau & Gobeil 2011).  
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Potential sources of discrepancy from reported screens of the Hh pathway might include 
screening modality, cell culture system, RNAi library utilized, method of pathway 
stimulation, and the criteria applied to determine which candidates qualify as hits (Table 
2.1).  Each of these potential sources of discrepancy is discussed below. 
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Table 2.1 Comparison of published RNAi screens identifying components of the 
Hh signaling pathway.  Published RNAi screens vary in their methodology by 
features such as RNAi modality, cell culture system assayed, screening library 
applied, the stimulation and read-out protocol, and by the analysis and hit criteria set 
to identify hits.  These methodological differences may account for differences in 
reported findings. (F) = F luciferase, (R) = R luciferase. 
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Table 2.1 (continued): 
Author RNAi 
Modality 
Cell Culture 
System 
Screening 
Library 
Stimulation 
and Read-
Out 
Analysis and 
Hit Criteria 
Lum et al. 
2003 
co-transfect 
dsRNA  
Drosophila 
clone 8 wing 
imaginal disc 
cell line 
co-transfect ptc-
luciferase (F) 
and copia-
Renilla 
Drosophila 
kinome and 
phospha-
tome; 
(generated 
within lab) 
~30hr after 
transfection, 
stimulate with 
media 
containing 
Hh-N for 
24hr. 
Dual-
Luciferase 
Assay Kit 
(Promega) 
Normalize 
(F)/(R). 
Basal luciferase 
activity  
(-Hh): > 5 SD. 
Fold induction 
(+Hh/-Hh):     
<-1.75 SD. 
Nybakken et 
al. 2005 
co-transfect 
dsRNA  
Drosophila 
clone 8 wing 
imaginal disc 
cell line 
co-transfect ptc-
luciferase (F) 
and pol-III 
Renilla 
co-transfect 
construct 
expressing full-
length Hh 
(pAc5C-Hh) 
Genome-
wide 
21,000 
dsRNAs; 
(Drosoph-
ila RNAi 
Screening 
Center) 
Assay 5 days 
after 
transfection. 
Dual-Glo 
Assay Kit 
(Promega) 
Normalize 
(F)/(R). 
Normalize to 
within-plate, 
internal-well 
negative 
control. 
Average z-
scores from 
replicate plates. 
z score <-2 or 
>3. 
Evangelista 
et al. 2009 
transfect 
single 
siRNA  
S12 (derivative 
of C3H10T1/2 
fibroblasts), 
stable Gli-luc 
(F) 
no non-
responsive 
reporter for 
normalization 
Kinome 
812 unique 
Kinases; 
(Dharma-
con) 
64hr after 
transfection, 
stimulate with 
Octyl-
modified Shh 
for 24hr. 
Steady Lite 
Reagent 
(Perkin 
Elmer) 
Log-transform 
(F). 
Normalize to 
noncoding 
within-plate 
control. 
Average 
triplicates. 
Subtract -Hh 
condition value 
from +Hh 
condition. 
<-1.5 SD from 
mean.  >=2 
siRNAs/gene. 
Table 2. 1 Comparison of published RNAi screens identifying components of the Hh signaling 
pathway 
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Table 2.1 (continued): 
Author RNAi 
Modality 
Cell Culture 
System 
Screening 
Library 
Stimulation 
and Read-
Out 
Analysis and Hit 
Criteria 
Hillman et 
al. 2011 
transfect 
dsRNA 
pools 
SL2 (derivative 
of NIH3T3 
cells), stable Gli-
Luc (F), stable 
renilla luciferase 
(R) 
Regulators 
of signal 
trans-
duction; 
816 
siRNA 
pools 
24hrs after 
transfection, 
stimulate with 
media 
containing 
Shh for 24-
30hr. 
Dual-Glo 
Assay Kit 
(Promega) 
Normalize 
(F)/(R)  
Normalize to 
within-plate 
control.  Remove 
siRNA pools with 
(R)<30% 
compared to 
negative control 
well. z score      
<-1.5 
Eisner 
(un-
published) 
lentivirus 
infection; 
shRNA 
SL2 (derivative 
of NIH3T3 
cells), stable Gli-
Luc (F), stable 
renilla luciferase 
(R) 
Phospha-
tome 320 
gene 
products 
(Broad 
Broad 
Institute 
RNAi 
Consort-
ium) 
72hrs after 
infection, 
stimulate with 
media 
containing 
Shh or SAG 
for 72hrs. 
Dual-
Luciferase 
Assay Kit 
(Promega) 
Normalize 
(F)/(R).  Remove 
shRNAs with 
(R)=0 in either 
stimulation. 
condition  
Average replicate 
(F)/(R)values.  
Log-transform 
(F)/(R).  Robust z 
score  <-1.5 or 
>1.5.  >=2 
shRNA/gene 
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While siRNAs and shRNAs both deplete targeted gene products, the difference in 
the route of administration (i.e., transient lipid-based transfection or electroporation vs. 
virally-mediated stable genome incorporation) may result in differences in the duration of 
knock-down, as well as in the efficiency of RNAi, particularly if the cell type is not easily 
transfected.  It is possible these differences may alter the observed phenotype following 
knock-down.   
While many principals of Hh signaling are conserved between Drosophila and 
mammals (reviewed in Robbins et al. 2012; Ingham et al. 2011; Wilson & Chuang 2010), 
Drosophila-specific aspects of Hh signaling would not be detected in a mammalian 
culture system and vice versa, justifying the need for screening in both cell culture 
systems.   
The RNAi library utilized for screening can also affect the results of the screen.  
By design, the library determines which gene products will be tested for a role in the 
signaling pathway under observation.  For example, a library containing only kinases 
would only provide the opportunity to identify relevant kinases in a pathway and not 
relevant phosphatases.  In addition, an RNAi library may not be fully verified resulting in 
false negatives due to poor knock-down or off-target effects.  In a screen for disease-
associated genes common to Hh and Wnt signaling, Jacob et al. (2011), screened two 
libraries in parallel, one from Dharmacon and one from Qiagen.  Of 535 genes of interest 
identified as hits by either library, only five genes were identified as hits in both libraries 
(Jacob et al. 2011).  This suggests that the results of an RNAi screen depend heavily on 
the high-throughput screening platform and/or library used. 
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The method and timing of Hh pathway stimulation may be another factor 
affecting the relative importance of a gene product in the pathway.  Hh signaling involves 
many complicated feedback loops (reviewed in Ribes & Briscoe 2009) and it is 
conceivable that the importance of a protein in the pathway would vary at different time-
points post-stimulation.  For this reason, it is possible that stimulating cells with an 
exogenous Hh ligand may yield different results than constitutively expressing Hh in the 
cell system.  Similarly, a 24-hour stimulation protocol may produce different results than 
a 48-hour stimulation protocol. 
After an RNAi screen has been conducted and raw primary data have been 
collected, the method of data analysis, exclusion criteria, and hit criteria applied 
determine which candidates quality as hits.  Without standardized analysis methods, this 
may further explain variation among the hits identified in published Hh screens. 
Motivation for a Phosphatome RNAi Screen 
Protein phosphorylation and consequent de-phosphorylation underlie an 
enormous spectrum of physiological functions.  The phosphorylation state of a substrate 
can modulate its activity, cellular localization, and/or binding to other proteins.  Aberrant 
phosphorylation is associated with many cancers; kinases, which catalyze 
phosphorylation, serve as therapeutic targets (reviewed in Cohen 2002; Blume-Jensen & 
Hunter 2001).  Thus, understanding the regulation of phosphorylation is crucial for 
understanding cellular biology in healthy and diseased states.  
While two mammalian screens have been conducted specifically to identify novel 
kinases in the Hh signaling pathway (Evangelista et al. 2008; Varjosalo et al. 2008), none 
have been conducted to specifically examine the role of phosphatases, which catalyze the 
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removal of phosphate groups.  Additionally, very few phosphatases have been identified 
as regulators of Hh signal transduction in broader or genome-wide RNAi screens 
(Hillman et al. 2011; Jacob et al. 2011; Nybakken et al. 2005).   
Just as the phosphorylation of substrates is important to transduce a signal, 
dephosphorylation may be an equally important regulatory mechanism.  For this reason, 
in collaboration with the Broad Institute RNAi Consortium, we conducted a screen for 
novel phosphatases acting in the Hh pathway.  It is our hope that these studies will 
advance our understanding of Hh biology while providing potential therapeutic targets 
for Shh-related cancers such as MB.   
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Results 
Phosphatase Inhibitors Alter Hh Pathway Activation 
Before conducting our RNAi screen to identify novel phosphatases in the Hh 
signaling pathway, we first verified that phosphatase activity is important for Hh pathway 
activation and that the impact of phosphatases on Hh pathway activity can be measured.  
We applied phosphatase inhibitors to Hh-responsive cells shortly before stimulating the 
pathway and measured the ability of cells to respond to stimulation.   
We measured pathway activation using ShhLightII (SL2) cells which are derived 
from NIH3T3 cells stably expressing a Gli-dependent firefly luciferase (F luciferase) 
reporter and constitutive pRL-TK Renilla luciferase (R luciferase; Taipale et al. 2000).  
Accordingly, SL2 cells produce F luciferase in response to Hh pathway stimulation and 
continually produce R luciferase.  The amount of F luciferase and R luciferase produced 
by cells are independently measured using commercially available luciferase assay 
reagents that generate quantifiable light reactions.  The F luciferase value serves as a 
readout for Hh pathway activation while the R luciferase value allows for normalization 
to cell number and/or potential differences global transcriptional activity.  In these 
experiments we measure pathway activation as F luciferase normalized to R luciferase 
(F/R luciferase). 
To test whether phosphatase activity regulates the Hh signaling pathway, we 
applied phosphatase inhibitors to SL2 and measured the impact of the inhibitors on the 
ability of cells to respond to stimulation by SAG, a small molecule Smo agonist (Chen et 
al. 2002).  We tested Okadaic Acid, a protein serine/threonine phosphatase inhibitor, and 
Sodium Orthovanadate (Na3VO4), a protein tyrosine phosphatase and alkaline 
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phosphatase inhibitor.  F/R luciferase values for SAG-stimulated cells treated with 
Okadaic Acid showed a very strong trend towards a reduced response to SAG compared 
to uninhibited cells treated with a vehicle (veh) control (Figure 2.1a).  Interestingly, 
application of Na3VO4 had a potent and dose-dependent effect increasing the F/R 
luciferase value regardless of pathway stimulation by SAG (Figure 2.1b).  These data are 
striking because they demonstrate an ability of Na3VO4 to activate the pathway in a 
ligand-independent manner.  It is important to note that the effects of Okadaic Acid and 
Na3VO4 on F/R luciferase values are largely the result of changes in F luciferase; R 
luciferase values were not dramatically altered by phosphatase inhibitors (data not 
shown).   
These data provide evidence that phosphatases are involved in the Hh signaling 
pathway.  Furthermore, these data suggest that phosphatases could be acting as potent 
positive and as negative regulators of Hh signal transduction.  As pharmacological 
phosphatase inhibitors have multiple targets, we next conducted an RNAi screen to 
identify individual phosphatases that regulate Hh signaling. 
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Figure 2. 1 Phosphatase inhibitors alter Hh pathway activation 
 
Figure 2.1 Phosphatase inhibitors alter Hh pathway activation.  F/R luciferase 
values following stimulation with veh or SAG (300nM) were altered following the 
application of phosphatase inhibitors for 45 minutes prior to stimulation.  A) Okadaic 
Acid trends towards a reduction in pathway stimulation at 12.5nM, normalized to 
untreated (veh, No Treatment) condition (N=7). B) Na3VO4 increases pathway 
activation at 100uM in both veh and SAG, normalized to untreated (veh, No 
Treatment) condition (N=9). Paired Student’s t-test with Bonferroni correction, 
*p<0.05; error bars = SEM.    
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Primary Screen Results 
RNAi was achieved using pLKO.1 lentiviral shRNA constructs generated by the 
Broad Institute RNAi Consortium against the mouse phosphatome.  This library was 
composed of 320 genes, with four or five unique shRNAs targeting each gene product.  
The screen included a plate of “negative control” shRNAs which targeted genes not 
present in these cells (e.g., GFP, RFP, β-galactosidase [LacZ]).  In addition, negative 
control shRNAs were added to each screening plate.  Two shRNAs targeting Smo were 
included on each screening plate as positive controls.  The screen was conducted in four 
“batches”, with replicates run in parallel.   
Before conducting the RNAi screen we optimized our screening assay for several 
parameters including cell density for seeding, the concentration of virus containing 
shRNA, time-course of adding reagents, and the luciferase reporter kit used to measure 
luciferase levels (data not shown).  We also confirmed that we had achieved high viral 
infection efficiency in SL2 cells by showing R luciferase values of infected cells are 
similar with and without puromycin selection (Figure 2.2a).  The pLKO.1 lentiviral 
shRNA constructs used in our experiments convey puromycin resistance.  Similar R 
luciferase values with and without puromycin selection suggest similar numbers of cells 
are present, indicating that the majority of cells are puromycin resistant and therefore 
infected with high efficiency.  Uninfected cells appear dead by light microscopy after 
puromycin treatment and have an R luciferase value equal to zero, confirming puromycin 
sensitivity in uninfected SL2 cells and a correlation between the R luciferase value and 
cell number (Figure 2.2b). 
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Figure 2. 2 SL2 cells have high infection efficiency 
 
Figure 2.2 SL2 cells have high infection efficiency.  A) R luciferase values of SL2 
cells infected with negative control shRNA are similar with or without puromycin 
selection (R
2
 = 0.81 in the SAG stimulation condition; R
2
 = 0.86 in the Shh 
stimulation condition). B) R luciferase values of uninfected SL2 cells equal zero 
confirming that uninfected cells are puromycin sensitive.  
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The screen was conducted as follows: 24 hours after SL2 cells were plated, virus 
encoding a single shRNA was added to each well.  The next day, cells were selected for 
successful infection with puromycin.  After two days of selection, cells had grown to 
confluency and the Hh pathway was stimulated using either Shh-conditioned media, 
SAG, or veh.  72 hours post-stimulation, cells were lysed and assayed for luciferase 
levels (Figure 2.3).   
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Figure 2. 3 RNAi screen schematic 
 
 
Figure 2.3 RNAi screen schematic.  A) Cells were plated in 96-well plates.  B) 24 
hours after plating, cells were infected with virus encoding a single shRNA targeting a 
phosphatase gene product.  C) After 24 hours of infection, media was removed and 
cells were selected for successful infection with 4ug/ml puromycin.  D) After 48 hours 
of selection, media was removed and cells were stimulated with Shh-conditioned 
media, SAG, or veh in low-serum media.  E) 72 hours after stimulation, cells were 
lysed and assayed for luciferase levels. 
 
 38 
 
Before analyzing the screen, we first ensured successful stimulation of the Hh 
pathway.  Average F/R luciferase data for each stimulation condition from the screen 
show that Shh and SAG successfully stimulated the pathway relative to the unstimulated 
veh condition (Figure 2.4a).   
To begin the primary screen analysis, we first excluded wells with low cell 
survival.  When the R luciferase value for either replicate was equal to zero, that shRNA 
was eliminated from analysis in that stimulation condition because this indicated that the 
cells were dead, possibly due to poor infection efficiency followed by puromycin 
selection or because the phosphatase targeted was necessary for cell viability.  We then 
normalized F luciferase to R luciferase and substituted all F/R luciferase values equal to 
zero for a value of 1x
10-6
; this value is lower than any measured F/R luciferase ratio.  We 
did this to avoid taking the natural log of zero in subsequent steps of the analysis (see 
below).  We next averaged the F/R luciferase ratios for the two replicates because the 
replicates were close (Figure 2.4b). 
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Figure 2.4 Primary screen results.  A) Average F/R luciferase values for each 
stimulation condition of the primary screen confirm that SAG and Shh stimulation 
activated the Hh pathway (N=1720 wells/stimulation condition), error bars = SEM. B) 
Replicate plates of SAG-stimulated cells infected with shRNA show similar F/R 
luciferase values (R
2
=0.7). C) Replicate F/R luciferase values were averaged for each 
shRNA in each stimulation condition and then converted to their natural log value.  
Rank-ordered natural log values show a range of responses to Shh and SAG 
stimulation.  D)  Scatter plot of primary screen robust z-score results.  Natural log 
values were assigned a robust z-score.  Genes with two or more hairpins with a robust 
z-score less than -1.5 (below the lower black line) or grater than 1.5 (above the top 
black line) were considered hits for further analysis.  shRNAs with an average F/R 
luciferase value equal to zero are not shown in D). 
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Figure 2.4 (continued): 
 
Figure 2. 4 Primary screen results 
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To identify which shRNAs were hits, we converted the averaged F/R luciferase 
ratios to natural log values (Figure 2.4c) and assigned each shRNA a robust z-score based 
on all the values collected in that batch for that stimulation condition (Figure 2.4d).  A z-
score describes the number of standard deviations a sample is from the mean.  A robust z-
score differs from a z-score by using the median instead of the mean and the median 
absolute deviation rather than the standard deviation when assigning values (Birmingham 
et al. 2009).  This desensitizes the analysis to outliers and makes our substitution of 1x
10-6
 
for F/R luciferase values equal to zero irrelevant.  Genes with two or more targeting 
shRNAs with a robust z-score less than -1.5 and genes with two or more targeting 
shRNAs with a robust z-score greater than 1.5 were considered hits.  Genes were 
considered hits if targeting shRNAs met the z-score criteria in the Shh and/or SAG 
stimulation conditions (e.g., a gene with two targeting shRNAs that had z-scores less than 
-1.5 in the SAG stimulation condition but not have any qualifying shRNAs in the Shh 
stimulation condition would be considered a hit as would a gene with one qualifying 
shRNA in the Shh stimulation condition and one qualifying shRNA in the SAG 
stimulation condition). 
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Of 320 gene products screened, 73 were identified as positive regulators of the 
pathway (i.e., shRNAs targeting these genes inhibited the ability of the cells to respond to 
Shh, resulting in a lower F/R luciferase value; Table 2.2) and 22 gene products were 
identified as negative regulators of the pathway (i.e., shRNAs targeting these genes 
increased the response of cells to pathway stimulation as indicated by an increased F/R 
luciferase value; Table 2.3).  Six gene products met criteria as both positive and negative 
regulators because a subset of shRNAs targeting those genes resulted in reduced F/R 
luciferase values while other shRNAs targeting those same genes resulted in increased 
F/R luciferase values (Table 2.4).  This result could be due to shRNA off-target effects.  
Alternatively, the shRNAs may target different splice variants of the phosphatase where 
one splice variant acts as a positive regulator and another functions as a negative 
regulator.   
Among many novel phosphatases, our screen also confirmed several phosphatases 
identified by previous RNAi screens for members of the Hh pathway including catalytic 
and regulatory subunits of Pp2a as well as Acp1, Dusp13, Pten, Ptp4a3, and Ptprn2 
(Nybakken et al. 2005; Hillman et al. 2011; Tables 2.2, 2.3, 2.4).  That Pp2a-encoding 
genes were identified as hits validates the ability of our screen to identify regulators of 
the pathway.   
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Table 2.2 Positive regulators of Hh signaling identified in the primary screen.  
Genes identified as positive regulators in the primary screen listed by gene symbol, 
RefSeq number, and NCBI Gene ID.  A subset of genes identified as positive 
regulators of Hh signaling in the primary screen were re-screened using an adapted 
screen setup (Rescreened).  A subset of genes re-screened were further identified as 
negative or positive regulators of Hh signaling (Re-Screen Hit; italics indicate genes 
identified as negative regulators in the re-screen).  A subset of the genes identified in 
our primary screen have been implicated in Hh signaling in prior Hh RNAi screens 
(Previously Identified). 
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Table 2.2 (continued): 
Symbol RefSeq NCBI 
Gene ID 
Rescreened Re-Screen 
Hit 
Previously 
Identified 
Acp1 NM_021330 11431 Acp1 Acp1 Hilman et al. 2011 
Acp5 NM_007388 11433       
Acpl2 NM_153420 235534 Acpl2     
Akp-ps1 XM_136795 208256 Akp-ps1     
Alpi XM_129951 76768 Alpi Alpi   
Alpl NM_007431 11647 Alpl     
Arid1a NM_033566 93760 Arid1a Arid1a   
BC005764 NM_181681 216152 BC005764     
Brd7 NM_012047 26992       
Cant1 NM_029502 76025 Cant1 Cant1   
Dusp11 NM_028099 72102 Dusp11     
Dusp21 XM_135794 73547 Dusp21     
Dusp26 NM_025869 66959 Dusp26 Dusp26   
Dusp28 NM_175118 67446 Dusp28 Dusp28   
Dusp8 NM_008748 18218       
Ebf2 NM_010095 13592 Ebf2     
Entpd4 NM_02617 67464 Entpd4     
Epb4.1l4a NM_013512 13824 Epb4.1l4a     
Eya1 NM_010164 14048 Eya1 Eya1   
Eya2 NM_010165 14049 Eya2 Eya2   
Fam48a NM_019995 56790 Fam48a     
Fbp1 NM_019395 14121 Fbp1     
G3bp1 NM_013716 27041       
G6pc2 NM_021331 14378 G6pc2     
Gfi1b NM_008114 14582 Gfi1b Gfi1b   
Gm5601 XM_485994 434233 Gm5601     
Impa2 NM_053261 114663 Impa2     
Inpp5d NM_010566 16331 Inpp5d Inpp5d   
Mfn1 NM_024200 67414    
Mtm1 NM_019926 17772 Mtm1     
Mtmr4 NM_133215 170749 Mtmr4     
Olfr1231 NM_146454 258446       
Olfr1265 NM_146343 258340       
GA_x5J8B
7W2BV0-
3116-4045 
NM_146263 257663       
Olfr140 NM_020515 57272 Olfr140     
Olfr1506 NM_146265 257665 Olfr1506 Olfr1506   
Pdxp NM_020271 57028       
Pfkfb4 NM_173019 270198       
Phlpp1 XM_129968 98432 Phlpp1     
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Table 2.2 (continued): 
Phlpp2 XM_146511 244650 Phlpp2     
Pou2f2 NM_011138 18987 Pou2f2     
Ppm1a NM_008910 19042       
Ppm1k NM_175523 243382 Ppm1k     
Ppp1cb NM_172707 19046 Ppp1cb Ppp1cb   
Ppp2r3a XM_135153 235542 Ppp2r3a   Nybakken et al. 
2005 
Ppp2r5a NM_144880 226849 Ppp2r5a   Nybakken et al. 
2005 
Ppp5c NM_011155 19060       
Ppp6c NM_024209 67857       
Psph NM_133900 100678       
Pten NM_008960 19211     Hilman et al. 2011 
Ptp4a2 NM_008974 19244 Ptp4a2     
Ptp4a3 NM_008975 19245 Ptp4a3   Hilman et al. 2011 
Ptpn14 NM_008976 19250    
Ptpn22 NM_008979 19260 Ptpn22 Ptpn22   
Ptprc NM_011210 19264       
Ptprg NM_008981 19270 Ptprg Ptprg   
Ptprj NM_008982 19271       
Ptprn NM_008985 19275       
Ptprq XM_137234 237523 Ptprq     
Ptprs NM_011218 19280       
Ptprt NM_021464 19281       
R3hdm2 NM_027900 71750 R3hdm2 R3hdm2   
Rngtt NM_011884 24018       
Sgpp2 NM_001004
173 
433323       
Sh2d1b1 NM_012009 26904    
LOC43624
4 
XM_488395 436244 LOC381574   
LOC38157
4 
XM_485481 381574    
Smarca4 NM_011417 20586    
Smarcc1 NM_009211 20588    
Ssh2 NM_177710 237860    
Stat3 NM_011486 20848    
Styxl1 NM_029659 76571    
Synj2 NM_011523 20975    
Table 2. 2 Positive regulators of Hh signaling identified in the primary screen 
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Symbol RefSeq NCBI Gene ID Rescreened Re-Screen Hit Previously 
Identified 
Acaca   107476       
Atp6v0e NM_025272 11974 Atp6v0e Atp6v0e   
C79127 NM_177691 232941       
Dupd1 XM_487320 435391 Dupd1 Dupd1   
Dusp13 NM_013849 27389     Hilman et al. 
2011 
Dusp18 NM_173745 75219       
Enoph1 NM_026421 67870 Enoph1     
Mtmr6 NM_144843 219135 Mtmr6     
Nt5e NM_011851 23959       
Olfr1199 NM_146458 258450 Olfr1199     
Ppap2c NM_015817 50784       
Ppp2ca NM_019411 19052 Ppp2ca Ppp2ca Nybakken et 
al. 2005 
Ppp2r5b NM_198168 225849 Ppp2r5b Ppp2r5b Nybakken et 
al. 2005 
Ppp3cc NM_008915 19057       
Ppp3r1 NM_024459 19058       
Ptpn1 NM_011201 19246       
Ptpn3 XM_355486 19257       
Ptprf NM_011213 19268       
Ptprn2 NM_011215 19276     Hilman et al. 
2011 
Ptpru NM_011214 19273 Ptpru Ptpru   
Ptprv NM_007955 13924 Ptprv Ptprv   
Sirpa NM_007547 19261       
Table 2. 3 Negative regulators of Hh signaling identified in the primary screen 
 
Table 2.3 Negative regulators of Hh signaling identified in the primary screen.  
Genes identified as negative regulators in the primary screen listed by gene symbol, 
RefSeq number and, NCBI Gene ID.  A subset of genes identified as negative 
regulators of Hh signaling in the primary screen were re-screened using an adapted 
screen setup (Rescreened).  A subset of genes re-screened were further identified as 
negative or positive regulators of Hh signaling (Re-Screen Hit; italics indicate genes 
identified as negative regulators in the re-screen).  A subset of the genes identified in 
our primary screen have been implicated in Hh signaling in prior Hh RNAi screens 
(Previously Identified). 
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Symbol RefSeq NCBI 
Gene ID 
Rescreened Re-Screen Hit Previously 
Identified 
Arpp21 NM_033264 74100 Arpp21     
Dusp19 NM_024438 68082 Dusp19     
Dusp4 NM_176933 319520 Dusp4     
Impa1 NM_018864 55980 Impa1 Impa1   
Nudt6 NM_153561 229228 Nudt6 Nudt6   
Ppapdc1a XM_355946 381925 Ppapdc3     
Table 2. 4 Genes identified as positive and negative regulators of Hh signaling in the primary screen 
Table 2.4 Genes identified as positive and negative regulators of Hh signaling in 
the primary screen.  Genes identified as negative and positive regulators in the 
primary screen listed by gene symbol, RefSeq number, and NCBI Gene ID.  These 
genes were re-screened using an adapted screen setup (Rescreened).  A subset of 
genes re-screened were further identified as negative or positive regulators of Hh 
signaling (Re-Screen Hit; italics indicate genes identified as negative regulators in the 
re-screen).  None of these genes have previously implicated in Hh signaling in prior 
Hh RNAi screens (Previously Identified). 
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Primary Screen Validation 
To confirm our primary screen results, we re-screened 57 of our hits using the 
same screen setup with two minor technical improvements (see methods; Tables 2.2, 2.3, 
2.4).  Because these shRNAs were selected for their effect on the pathway from the first 
screen, analyzing the second screen with a robust z-score may have skewed our results.  
Therefore, to evaluate the effect of shRNAs on Hh pathway induction in the second 
screen, we compared the F/R luciferase value of each shRNA to the F/R luciferase value 
measured from cells treated with negative control virus.  We screened a 96-well plate of 
cells treated with unique negative control shRNAs and recorded the median F/R 
luciferase value following stimulation with Shh, SAG or veh.  We reasoned this median 
negative control F/R luciferase value was representative of an unperturbed Hh pathway 
response to stimulation and looked for shRNAs targeting phosphatases which blocked the 
ability of the cells to respond to stimulation or sensitized the response relative to this 
value.  To determine which primary screen hits were considered hits in the second screen, 
we set a criteria whereby shRNAs with an F/R luciferase value less than 25% of the 
median negative control F/R luciferase value were identified as positive regulators of the 
pathway (Figure 2.5c-d); shRNAs with an F/R luciferase value greater than four-fold the 
median negative control F/R luciferase value were identified as negative regulators of the 
pathway (Figure 2.5a-b).  We only considered genes for which 25% or more of shRNAs 
targeting that gene met the above F/R luciferase value criteria.   
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Figure 2.5 Re-screen results.  A subset of hits from the primary screen were re-
screened.  Pink squares indicate values corresponding to shRNAs targeting Eya1 or 
Smo.  F/R luciferase values are normalized to the median F/R luciferase value of 
negative control shRNAs.  A) F/R luciferase values rank-ordered show a range of 
responses to Shh and SAG stimulation.  B) F/R luciferase values as a scatter plot show 
a range of responses to Shh and SAG stimulation.  Values greater than four-fold the 
F/R luciferase value of negative control shRNAs (above the black line in A and B) are 
considered hits.  C) Magnified portion of the rank-order graph in A.  D) Magnified 
portion of the scatter plot in B.  Values less than 25% the F/R luciferase value of 
negative control shRNAs (below the block line in C and D) are considered hits. 
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Figure 2.5 (continued): 
 
Figure 2. 5 Re-screen results 
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Of 57 genes re-screened, 14 came out as positive regulators of the pathway and 
nine were identified as negative regulators of the pathway (Tables 2.2, 2.3, 2.4).  Again, 
shRNAs targeting Smo and known phosphatases came out as hits in the screen including 
Pp2 catalytic and regulatory subunits. 
Phosphatases Likely Important for Shh-Dependent MB  
To select which hits to pursue for further study, we looked for phosphatases more 
likely to be involved in Shh-dependent MB.  There are multiple subtypes of MB defined 
by distinctive gene expression profiles; the “Shh-subtype” of MB is characterized by 
aberrant expression of Hh pathway components and increased Hh pathway activation 
(reviewed in Northcott et al. 2012).  Utilizing three previously published sets of MB gene 
expression data (Kool et al. 2008; Northcott et al. 2011; Thompson et al. 2006), we asked 
if any of our hits are also up- or down-regulated in the Shh-subtype of MB relative to 
other MB subtypes.  Of the 39 hits from our primary screen that were not re-screened, 10 
showed specific up- or down-regulation in the Shh-subtype of MB relative to other MB 
subtypes in one or more data-sets; one gene (Ppm1a) was identified in two published data 
sets (Table 2.5).  Of the 23 hits identified following re-screening, nine showed specific 
up- or down-regulation in Shh-subtype MB relative to other MB subtypes.  Of these, 
three genes (Cant1, Eya1, Eya2) were noted in two or more data sets (Table 2.6).   
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Symbol 
Direction 
of 
Regulation 
Screen 
Kool et al. 2008 
direction of 
regulation in MB 
Thompson et al. 2009 
direction of 
regulation in MB 
Northcott et al. 2010 
direction of 
regulation in MB 
Acaca Negative     down 
Mfn1 Positive     up 
Nt5e Negative     up 
Pdxp Positive down     
Ppm1a Positive down down down 
Ppp6c Positive     down 
Psph Positive down     
Ptprt Positive   down   
Smarca4 Positive     down 
Smarcc1 Positive   up   
Table 2. 5 Genes identified in the primary screen that were not re-screened have been reported to be 
up- or down-regulated in Shh-dependent MB 
Table 2.5 Genes identified in the primary screen that were not re-screened have 
been reported to be up- or down-regulated in Shh-dependent MB.  Of the 39 hits 
from our primary screen identified as positive or negative regulators of Hh signal 
transduction that were not re-screened, 10 (Symbol) have specific up- or down-
regulation in the Shh-subtype of MB relative to other MB subtypes as reported in one 
or more of three published gene expression studies (Kool et al. 2008; Thompson et al. 
2009; Northcott et al. 2010).  
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Symbol 
Direction 
of 
Regulation 
Screen 
Kool et al. 2008 
direction of 
regulation in MB 
Thompson et al. 
2009 direction of 
regulation in MB 
Northcott et al. 
2010 direction of 
regulation in MB 
Arid1a Positive     down 
Cant1 Positive down   down 
Dusp26 Positive     up 
Eya1 Positive   up up 
Eya2 Positive down down down 
Impa1 Negative down     
Inpp5d Negative     up 
Ppp2ca Negative   down   
Ptpru Negative     down 
Table 2. 6 Genes identified in the primary screen that were re-screened have been reported to be up- 
or down-regulated in Shh-dependent MB 
Table 2.6 Genes identified in the primary screen that were re-screened have been 
reported to be up- or down-regulated in Shh-dependent MB.  Of the 23 hits 
identified as hits following re-screening, nine (Symbol) have specific up- or down-
regulation in the Shh-subtype of MB relative to other MB subtypes as reported in one 
or more of three published gene expression studies (Kool et al. 2008; Thompson et al. 
2009; Northcott et al. 2010).   
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From the list of genes that appeared in two or more MB databases as being up- or 
down-regulated in Shh-subtype MB relative to other MB subtypes (i.e., Ppm1a, Cant1, 
Eya1, Eya2), we choose to pursue the role of Eya1 because the effect on Hh pathway 
activation of knocking-down this gene in SL2 cells is consistent with the direction of 
deregulation in Shh-subtype MB.  In the SL2 cells, knocking-down Eya1 blocked the 
ability of the cells to respond to stimulation, suggesting Eya1 is a positive regulator of the 
pathway.  In MB cells, where the pathway is known to be overly active, Eya1 is up-
regulated, also consistent with the idea that Eya1 is a positive regulator of the pathway.  
In contrast, the other three hits identified in our screen and found to be specifically 
regulated in Shh-subtype MB (Ppm1a, Cant1, and Eya2) were identified as positive 
regulators of Hh signal transduction by our RNAi screen in SL2 cells but were found to 
be down-regulated in Shh-dependent MB cells. 
In addition, we also chose to pursue the role of Eya1 in Hh signaling given 
overlapping roles of Eya1 and Shh signaling in disease and development to be discussed 
in the following chapter. 
 
 55 
 
Discussion 
In this study, we conducted an RNAi screen identifying novel phosphatases in the 
Hh signaling pathway.  In addition, several phosphatases previously implicated in Hh 
signaling were identified in our screen, validating our system.  Phosphatases identified in 
our screen contribute to our understanding of this important signaling pathway and may 
serve as future therapeutic targets in treating Shh-dependent cancers. 
Phosphatase Inhibitors   
 For a preliminary look at the potential necessity of phosphatases for Hh signaling, 
we measured the ability of SL2 cells to respond to SAG following treatment by a 
serine/threonine protein phosphatase inhibitor or an inhibitor to tyrosine phosphatases 
and alkaline phosphatases.  Our findings confirmed that dephosphorylation may be an 
important regulatory mechanism in Hh signaling. 
Okadaic Acid strongly inhibits Pp1, Pp2A, and Pp2B.  1-2nM concentrations of 
Okadaic Acid will result in a 50% reduction in enzymatic activity (ID50) of Pp2A; Pp1 
has an ID50 ~300nM and Pp2B has an ID50 of 4-5uM concentrations of Okadaic Acid 
(Bialojan & Takai 1988).  Our finding that 12.5nM Okadaic Acid blocks the ability of 
cells to respond to SAG is consistent with previous reports implicating Pp2A in the Hh 
pathway (Jia et al. 2009; Jin et al. 2011; Krauss et al. 2008) as well as with our own 
primary screen data identifying Pp2A encoding genes as hits. 
Na3VO4 is an inhibitor of protein tyrosine phosphatases, alkaline phosphatases, 
and ATPases and is used at mM concentrations (Kim et al. 1999).  Our preliminary 
finding that Na3VO4 activates the Hh pathway at 50uM concentrations is very intriguing.  
Therefore, this class of phosphatase was of particular interest to us in conducting our 
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phosphatome RNAi screen.  Of 101 primary screen hits, at least 21 are potential Na3VO4 
targets (see discussion below).   
RNAi Screen Design and Analysis 
In any experiment, an investigator must carefully design his or her study to 
minimize false positive and false negative results.  This is especially true in designing 
and analyzing a screen which returns a graded and continuous range of results (e.g., a 
continuous range of z-scores).  As such, determining criteria for which gene candidates 
qualify as hits is subjective and different criteria will produce a different set of hits.   
In analyzing our screen, we took steps to minimize false positive and false 
negative results.  We assigned robust z-scores by batch to account for potential batch-to-
batch variation from slight differences in plating, stimulation, cell lysis, or other technical 
aspects of the screening protocol.  To minimize the number of false positive hits, we 
made our z-score criteria sufficiently stringent to exclude all negative control shRNAs as 
hits (i.e., multiple shRNAs targeting RFP, GFP, and LacZ).  These negative control 
shRNAs were selected because the genes they target are not expressed in this cell system 
and therefore the shRNAs should not alter the ability of cells to respond to Hh pathway 
stimulation.  To reduce the chance that an effect on Hh pathway stimulation was due to 
off-target effects of shRNA, we set a minimum criterion of two targeting shRNAs per 
gene.  To ensure our analysis detected negative regulators of the pathway, we also 
designed z-score criteria to be sufficiently generous to identify our positive controls 
(shRNAs targeting Smo and Luciferase).     
Despite our considerations, there remain several potential sources of false positive 
and false negative results.  As SL2 cells are maximally Shh-responsive when confluent 
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(data not shown), a potential source of false positive hits may include genes targeted by 
shRNA in virus with low infection efficiency.  After puromycin selection, wells treated 
with low-efficiency virus may not reach confluency and may therefore be less responsive 
to Shh and SAG, resulting in a low F/R luciferase ratio.  A potential source of false 
negative hits in our screen includes shRNA constructs which successfully entered cells 
and conveyed puromycin resistance but failed to sufficiently knock-down their target.  In 
addition, the timing of our assay may not have been optimal to detect phenotypes from 
knocking-down some phosphatases that impinge upon the pathway.   
RNAi Screen Results 
Interestingly, in the primary screen, we found evidence of many kinds of 
phosphatases influencing Hh pathway activation including protein phosphatases, protein 
tyrosine phosphatases, alkaline phosphatases, dual-specificity phosphatases, lipid 
phosphatases, and sugar phosphatases.  Among these, phosphatases encoded by Pp2, 
Acp1, Dusp13, Pten, Ptp4a3, and Ptprn2 may be promising candidates to pursue in future 
studies as targeting these genes altered Shh-responsiveness in our screen as well as in 
previous RNAi screens (Hillman et al. 2011; Nybakken et al. 2005).  Stat3 may be an 
additional interesting candidate to pursue as it has been previously implicated in 
hedgehog signaling (Yang et al. 2012).   
While knocking-down a direct regulator of Hh signaling would alter the response 
of SL2 cells to Shh or SAG, hits likely also include phosphatases acting indirectly on the 
pathway.  For example, knocking-down a phosphatase needed to regulate a factor 
involved in trafficking Smo to the primary cilia might also affect the ability of cells to 
respond without being a core member of the pathway.  Further studies examining the 
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activity, cellular localization, and potential substrates of a candidate phosphatase would 
need to be carried out to understand how a candidate is functioning to regulate Hh signal 
transduction.  
In our experimental design, we included three stimulation conditions, Shh, SAG, 
and veh.  We included Shh, which activates the pathway through binding Ptch1, as well 
as SAG, which activates the pathway through direct Smo activation, with the hope of 
identifying phosphatases acting in the Hh pathway between Ptch1 and Smo as very little 
is known about the mechanisms mediating Ptch1 inhibition of Smo.  Unfortunately, 
however, we did not identify any hits which had an effect in the Shh stimulation 
condition while having no effect in the SAG stimulation condition.  While disappointing, 
this result is consistent with previous screening attempts (Evangelista et al. 2008).   
Encouraged by results that Na3VO4 has the ability to induce F luciferase in SL2 
cells, the veh stimulation in our screen condition provided an opportunity to identify 
strong negative regulators of Hh signaling in SL2 cells (i.e., phosphatases that, when 
knocked-down, result in ligand-independent pathway activation).  Unfortunately, of 
nearly 1,800 shRNAs screened, only eight had a robust z-score greater than 1.5 in the veh 
condition and these shRNAs targeted eight unique phosphatases, failing to meet our 
criteria requiring a gene have two qualifying targeting shRNAs to be considered a hit.  
However, two of the eight activating shRNAs targeted protein tyrosine phosphatases, 
Ptplad1 and Ptprm, which are potential targets of Na3VO4.  It is possible that knock-
down of a single gene product was unable to induce extraordinary high F luciferase 
values in veh-treated cells because the large effect observed by Na3VO4 application is the 
result of inhibiting multiple phosphatase targets simultaneously while our screen 
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examined the effect of knocking done single genes.  Additionally, around 40% of our veh 
samples had at least one replicate F luciferase equal to zero, suggesting SL2 cells have 
very low basal levels of Hh pathway activation.  Additionally, this observation suggests 
that the basal activity in SL2 cells is often below the level of detection by our assay.  
Perhaps by having so many samples with a zero reading, our median F/R luciferase value 
was artificially high in the veh condition, making it difficult to identify shRNAs which 
had modest activating affects on the pathway. 
We also looked for negative regulators of the pathway in the Shh and SAG 
stimulation conditions (i.e., shRNAs that enhanced the cells’ response to Hh pathway 
stimulation).  Of 22 phosphatases identified as having two or more targeting shRNAs 
with a robust z-score greater than 1.5, six were protein tyrosine phosphatases and 
potential targets of Na3VO4.  We also noticed that there were more than three times as 
many positive regulators of the pathway identified as hits than negative regulators.  One 
potential explanation for this could be that we were maximally stimulating the cells, 
leaving little room for enhanced pathway activation.  More sensitive experiments to 
identify positive pathway regulators might involve stimulating the pathway with SAG 
concentrations around 10-50nM (i.e., 6-30x less concentrated than was applied in our 
screen). 
The phosphatases identified in our screen contribute to our knowledge of the Hh 
signaling pathway.  By focusing on phosphatases more likely to be important in Shh-
dependent MB, it is our hope that this information may contribute to the development of 
cancer therapies.  Specifically, we chose to focus our studies on Eya1 which was the only 
hit to be shown by two independent studies to be significantly differentially regulated in 
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Shh-subtype MB while showing consistent effects on pathway activation by RNAi-
mediated knock-down.  In the next chapter we will pursue the role of Eya1 in Hh 
signaling. 
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Methods 
SL2 Cell Stimulation 
Shh-conditioned media: 293FT cells (derived from human embryonic kidney cells 
transformed with the SV40 large T antigen) were transfected with full-length Shh in a 
pcDNA3 vector using Lipofectamine 2000 (Life Technologies Catalog #11668019) 
following manufacturer’s instructions.  Media was changed the next day (~18 hours after 
transfection), 24 hours later media was changed a second time, 24 hours later media was 
collected and concentrated using Amicon Ultra centrifugal filter units (Millipore).  The 
presence of Shh ligand was verified by western blot (antibody: N-Shh19, Santa Cruz).  
Smo agonist, SAG (Enzo Life Sciences) was reconstituted in equal parts water and 
DMSO and stored at -20°C.  Veh treated samples were stimulated using equal parts water 
and DMSO.  When applying a phosphatase inhibitor before pathway stimulation, media 
was removed from each well and the inhibitor was added to the well in a volume of 30ul 
(at 1.7x concentration) for 45 minutes, after which 20ul of stimulation media (at 2.5x 
concentration) was added to the wells for a final volume of 50ul.   
 
SL2 Luciferase Assay  
For all SL2 luciferase assays, SL2 cells (ATCC Catalog # CRL-2795) were plated 
in 96-well opaque tissue culture dishes (Falcon Catalog #353296) and maintained in 
growth media (DMEM, 10% calf serum, 1unit/ml penicillin, 1ug/ml streptomycin, 
0.4mg/ml G418, and 0.15mg/ml zeocin).  In all SL2 stimulation experiments, growth 
media was removed and cells were stimulated with 300ng/ml SAG or the same volume of 
veh in low serum conditions (DMEM, 0.5% calf serum, 5mM HEPES).  To assay 
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pathway stimulation, media was removed and cells were lysed at room temperature for 15 
minutes on a rotator using Passive Lysis Buffer from the Dual Luciferase Reagent (DLR; 
Promega #E1960) kit.  Plates were stored at -20°C or assayed immediately for luciferase 
activity, following manufacturer’s instructions with the modification that we added 30ul 
Passive Lysis Buffer and 60ul of Luciferase Assay Reagent and 60ul of Stop & Glo to 
each well.    
 
RNAi Screen  
Lentiviral infections for the screen were performed using pLKO.1 lentiviral 
shRNA constructs generated the Broad Institute RNAi Consortium and arrayed in 96-
well plates.  SL2 cells were plated using a microfill cell dispensing machine.  24 hours 
later, polybrene (final concentration of 8ug/ml) and 10ul of virus containing a single 
shRNA were added to screening plates using an automated cell culture robot.  Plates were 
spun in a centrifuge at 2500rpm for 20 min at room temperature to enhance infection 
efficiency.  Each plate was prepared in duplicate.  Four hand-spiked shRNAs targeting 
RFP, GFP, or LacZ plus two shRNAs targeting Smo were included on each plate as 
negative and positive controls, respectively.  In addition, a plate of negative control 
shRNAs prepared in parallel with the phosphatome library was included in the screening 
set.  24 hours after plating, media was removed and cells were selected for infection by 
adding growth media containing 4ug/ml puromycin.  48 hours following selection, media 
was removed, cells were rinsed twice with low-serum media, and cells were stimulated 
using Shh-condition media, SAG, or veh in low-serum media.  72 hours following 
stimulation, stimulation media was removed and cells were lysed.  For the re-screen, cells 
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were plated in virus and polybrene, shortening the screening protocol by 24 hours.  For 
the re-screen cells were rinsed with PBS before lysis. 
 
RNAi Screen Analysis 
shRNAs with an R luciferase value for either replicate equal to zero were 
eliminated from analysis in that stimulation condition.  We next averaged the F/R 
luciferase ratios and F/R luciferase ratios equal to zero were given a value of F/R 
luciferase equal to 1x
10-6
.  We then took the natural log of the average F/R luciferase 
value.  We assigned each shRNA a robust z score [(x-median)/(median absolute 
deviation); median absolute deviation = median(abs(x- median))*1.4826] based on all the 
values collected in that batch.  For the primary screen, genes with two or more shRNAs 
targeting that gene with a robust z score less than -1.5 or greater than 1.5 in either the Shh 
or SAG stimulation conditions were considered hits.   
For the re-screen, we identified hits as having an F/R luciferase value less than 
25% or greater than four-fold the median F/R luciferase value from a plate of negative 
control shRNAs.  Genes with 25% or more of shRNAs targeting that gene were hits.  
Screen analysis was preliminarily conducted in Microsoft Excel and secondarily 
re-analyzed in Matlab. 
Author Contribution: 
Dr. Srividya Balasubramanian initiated our RNAi screen project and conducted 
initial protocol optimizations.  We conducted additional optimizations together and I also 
conducted optimizations independently.  The primary and second screens were conducted 
and analyzed in collaboration with Dr. So Young Kim, Leslie Wardwell, Dr. Anna 
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Schinzel, and Dr. William C. Hahn.  Dr. Alexandra Smolyanskaya assisted with the re-
analysis of screen data in Matlab.   
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CHAPTER 3: EYA1 IS A POSITIVE REGUALTOR OF HH 
SIGNAL TRANSDUCTION 
Introduction 
Rationale for Pursuing Eya1 in Hh Signaling  
 In selecting which hits from our RNAi screen to pursue as potentially important 
regulators of Hh signaling, we focused on genes specifically up- or down-regulated in 
human Shh-dependent MB as compared to other MB subtypes.  We made this decision 
for three reasons.  Firstly, the Hh signaling pathway is over-active in Shh-dependent MB 
and many Hh pathway components are up-regulated in those tumors; a difference in 
expression of a gene in Shh-dependent MB could indicate a role for the protein product 
encoded by that gene in the Hh signaling pathway.  Secondly, a greater understanding of 
MB biology could yield future therapeutic targets.  In addition, a phosphatase implicated 
in Hh signaling in these two very different contexts, human MB and murine embryonic 
fibroblasts, demonstrates a potentially generalizable function of that phosphatase in 
regulating Hh signal transduction. 
We identified Eya1 as a positive regulator of Hh signal transduction in our 
primary screen and Eya1 is also specifically up-regulated in Shh-dependent MB (Kool et 
al. 2008; Northcott et al. 2011; Thompson et al. 2006).  We additionally chose to pursue 
the role of Eya1 in Hh signaling because Eya1 and Hh signaling have overlapping roles 
in development from Drosophila to mammals.  In Drosophila, Hh and Eya are both 
crucial for eye development.  In vertebrate development, Eya1 and Shh overlap in the 
development of the otic vesicle, lung, and kidney. 
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Eya1 and Hh in Drosophila Eya Development 
Eya gets its name from its role in Drosophila eye development as a member of the 
RDGN (reviewed in Pappu & Mardon 2004; Silver & Rebay 2005).  The Drosophila 
visual system is comprised of two compound eyes and three ocelli.  The compound eyes 
contain ommatidia, structures comprised of photoreceptors and accessory cells; ocelli are 
simple light-sensitive organs at the top of the adult head.  Hh signaling is necessary for 
both compound eye and ocelli organ systems, and interacts genetically with the RDGN 
(Aguilar-Hidalgo et al. 2013; Blanco et al. 2009; Pappu et al. 2003). 
In the compound eye Eya and its co-factor, So, are required for the initiation and 
progression of photoreceptor differentiation.  In this developmental context, the role of 
Hh is to relieve CiR-mediated repression of Eya expression (Pappu et al. 2003).  In the 
absence of Hh signaling, CiR represses Eya expression, preventing the initiation and 
progression of photoreceptor differentiation.  Hh signaling inhibits the formation of CiR, 
allowing Eya induction.  The removal of CiR is sufficient to induce Eya expression while 
loss-of-function studies show that full-length CiA plays little or no role in photoreceptor 
development (Pappu et al. 2003). 
Hh signaling regulates Eya expression in the developing ocelli as well.  In 
contrast to the mechanism of transcriptional regulation in the compound eye, in ocellar 
precursor cells, CiA is responsible for Eya gene activation (Blanco et al. 2009).  In Smo 
mutant clones without Hh signaling, Eya is not expressed whereas in Ptc mutants clones 
with active Hh signaling, Eya expression is induced (Blanco et al. 2009).  While Hh 
signaling regulates Eya expression in Drosophila eye development, So regulates Hh 
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expression, creating a complex network intricately linking RDGN and Hh signaling in 
this context (Pauli et al. 2005).   
Much of the Hh signaling pathway described in Drosophila is conserved in 
mammalian Hh signaling (reviewed in Robbins et al. 2012; Ingham et al. 2011; Wilson & 
Chuang 2010).  Similarly, the RDGN as characterized in Drosophila has also been 
adapted to mammalian development (reviewed in Silver & Rebay 2005).  This precedent 
for Hh and RDGN pathway conservation from Drosophila to vertebrates and these 
examples of a genetic interaction between Hh and Eya in Drosophila eye development 
helped motivate our decision to pursue Eya1 in the context of mammalian Hh signaling. 
Nrp Biology  
Nrps are transmembrane proteins, functioning as co-receptors with roles in axon 
guidance and angiogenesis (reviewed in Pellet-Many et al. 2008; Parker et al. 2012).  
There are two mammalian Nrp genes, Nrp1 and Nrp2, which share the same domain 
structure and 44% amino acid homology (Giger et al. 1998).  Nrps have five external 
domains, a single transmembrane alpha helix, and a short intracellular domain. The 
extracellular domains consist of two tandem complement/Uegf/Bmp1 (CUB) domains, 
two tandem Factor V/VIII homology domains, and one Meprin/A5-antigen/ptp-Mu 
(MAM) domain.  The external domains bind ligands, including class III Semaphorin 
(Sema3) family members and vascular endothelial growth factor (VEGF) family 
members.  Nrp1 and Nrp2 bind distinct yet overlapping members of the Sema3 and 
VEGF families ( reviewed in Neufeld & Kessler 2008). 
Nrps bind Sema3s and function in axon guidance as co-receptors with Plexin 
proteins (He & Tessier-Lavigne 1997; Kolodkin et al. 1997; Takahashi et al. 1999).  
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Sema3s are secreted guidance factors, repelling axons during axonal path finding.  Within 
the Nrp-Plexin-Sema3 complex, Nrps bind Sema3s with high-affinity while Plexins 
transduce an intracellular signal resulting in the collapse of the actin cytoskeleton in the 
growth cone.  Nrps serve as obligate co-receptors in some, but not all, contexts of Sema3 
signaling (Gu et al. 2005).   
A second well-characterized function of Nrp is to bind VEGF as a co-receptor 
with VEGF receptors in angiogenesis (Soker et al. 1998; Gluzman-Poltorak et al. 2001).  
VEGF binds both a VEGF receptor and Nrp, perhaps bridging the two transmembrane 
proteins.  Nrps can serve to enhance VEGF binding to its receptor and strengthen VEGF 
receptor-mediated intracellular signaling (Soker et al. 2002).   
In addition to serving as a co-receptor in complexes where its partner transduces 
the lion’s share of intracellular signaling, Nrp may have independent intracellular 
signaling capabilities.  The Nrp intracellular domain contains three critical C-terminal 
amino acids that constitute a PDZ domain-binding motif, allowing Nrps to bind to PDZ 
domain proteins such as GAIP interacting protein, C terminus (GIPC; Cai & Reed 1999).  
This PDZ domain-binding motif may provide a mechanism for Nrp to directly transduce 
intracellular signaling. 
Consistent with roles of Nrps in axon guidance and angiogenesis, Nrp1 mutant 
mice die by E12.5-E13.5 with severe abnormalities in axon path finding and vascular 
defects (Kawasaki et al. 1999).  Nrp2 mutants survive to adulthood with less severe axon 
pathfinding and vascular phenotypes (Giger et al. 2000; Chen et al. 2000; Yuan et al. 
2002).  It is worth noting that Nrp1 and Nrp2 mutants display axon guidance defects in an 
overlapping but distinct set of nerves.  Nrp1/2 double-mutants die earlier than either 
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single mutant at E8.5, with a more severe abnormal vascular phenotype than either single 
knock-out mouse (Takashima et al. 2002).  Consistent with the characterization of Nrp 
mutant mice, the expression patterns of Nrp1 and Nrp2 are overlapping yet distinct in the 
developing embryo (Chen et al. 1997).  Together, these observations suggest Nrp1 and 
Nrp2 protein function is partially redundant in mammalian development. 
Nrp and Hh Signaling in Development and Disease 
Nrp1 and Nrp2 have been identified as positive regulators of Hh signal 
transduction in an RNAi screen (Hillman et al. 2011).  Hillman and colleagues (2011) 
show siRNA targeting Nrp1 and Nrp2 block the ability of SL2 cells to respond to Shh 
ligand or SAG as measured by multiple readouts for pathway activation.  Nrp1 and Nrp2 
are only partially redundant in this context as targeting both genes simultaneously 
provides the greatest inhibition of pathway stimulation.  In addition, Hillman et al. (2011) 
report that two non-overlapping morpholinos targeting nrp1a, a Zebrafish Nrp homolog, 
result in Zebrafish phenotype consistent with Hh loss of function.  This provides in vivo 
evidence for conserved role of Nrp in Hh signaling from bony fish to mammals. 
A role for Nrps in Hh signaling is consistent with Nrp expression patterns in areas 
where Hh signaling is important during mouse embryonic development.  These locations 
include the spinal cord, limb bud, and yolk sac.  Nrps are expressed in the ventral spinal 
cord at E10.5, a time when the ventral spinal cord cells are responsive to Shh ligand.  In 
addition to its role as a morphogen in the developing spinal cord, Shh also has a role in 
axon guidance as a chemoattractant for commissural neurons projecting to the floor plate 
(Charron et al. 2003).  After exposure to Shh ligands and having crossed the ventral 
midline, axons then become sensitive to Sema3 ligands, which bind Nrp2; 
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Sema3/Nrp2/Plexin signaling repels the axons, preventing them from doubling back into 
the floor plate or recrossing the midline (Zou et al. 2000).  Shh signaling from the floor 
plate activates the responsiveness of crossing axons to Sema3s so they become newly 
sensitive to Sema3 repulsion after crossing (Parra & Zou 2010).  This sequential 
sensitivity to Shh and Sema3 ligands may indicate cross-talk between the two signaling 
pathways. 
Nrps are expressed in the developing limb bud where Shh signaling is vital for 
digit patterning (Kitsukawa et al. 1995; Chen et al. 1997).  In its role in patterning digits, 
Shh signaling is needed to inhibit the formation of Gli3R (reviewed in Bastida & Ros 
2008).  In Shh-deficient limb buds, Gli3R gene repression results in a loss of digits; Gli3
-
/-
 limbs are polydactyllous (Hui & Joyner 1993; Chiang et al. 1996; Litingtung et al. 
2002).  Interestingly, chimera mice constitutively overexpressing exogenous Nrp1 also 
display extra digits (Kitsukawa et al. 1995).  The overlap of expression patterns and 
similarity of phenotypes suggest that Shh and Nrp signaling could interact in digit 
formation.  
The murine embryonic visceral yolk sac is a third location of active Hh signaling 
where Nrps are expressed and play a role in embryonic development (Hillman et al. 
2011).  Ihh and Ptch1 expression patterns and yolk sac phenotypes from Ihh
-/-
 and Smo
-/-
 
embryos demonstrate a role for Hh signaling in yolk sac vessel remodeling (Farrington et 
al. 1997; Maye et al. 2000; Byrd et al. 2002).  Nrp1/2 double-mutants also display errors 
in yolk sac vasculogenesis (Takashima et al. 2002). 
Finally, a recent paper has linked Nrp1 and Shh in MB (Snuderl et al. 2013).  
Placental Growth Factor (PGIF), a member of the VEGF family, promotes growth and 
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survival of tumor cells through Nrp1 signaling.  Snuderl and colleagues (2013) report that 
placental growth factor (PlGF) is expressed by tumor and stromal cells and that PlGF in 
the stroma is produced in response to Shh ligand secreted from the tumor.  While the 
exact role of PlGF in tumor growth is unclear, these studies suggest combined Shh and 
PlGF inhibition might represent a new target therapy for MB. 
In this chapter, we show Eya1 is a positive regulator of Hh signal transduction.  
Motivated by our RNAi screen results and previous studies linking Eya and Hh in disease 
and development, we investigate the effect of Eya1 knock-down on the ability of SL2 
cells to respond to Hh pathway stimulation.  We show that knock-down of Eya1, as well 
as knock-down of its co-factor and fellow RDGN-member, Six1, block the induction of 
Hh response genes.  Furthermore, we provide evidence that Eya1 and Six1 act on the Hh 
pathway by regulating the transcription of Nrp1 and Nrp2.  Furthermore, we show that 
Eya1 and Six1 act within the Hh signaling pathway downstream of Smo and at or above 
the level of Sufu.  
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Results 
Eya1 Blocks Hh Pathway Stimulation 
To pursue Eya1 as an important regulator of Hh signaling, we first verified that 
Eya1 shRNAs efficiently knock-down their target and block the ability of SL2 cells to 
respond to Hh pathway activation.   
We confirmed that Eya1 and Smo shRNAs knock-down their target mRNAs by 
quantitative real-time PCR (qRT-PCR; Figure 3.1a-b).  In these experiments we use 
shRNA targeting LacZ as a negative control because SL2 cells do not express LacZ; we 
use shRNA targeting Smo as a positive control because Smo is a potent positive regulator 
of Hh signaling. 
Unfortunately, Eya1 antibodies are unable to detect endogenous Eya1 protein 
(data not shown).  Therefore, to ensure shRNAs targeting Eya1 reduce Eya1 at the 
protein level, we tested the ability of shRNAs to reduce levels of overexpressed Eya1 
protein.  Co-expression of a full-length Eya1 construct with an shRNA targeting Eya1 
results in reduced levels of Eya1 protein in SL2 cells.  Co-expression of an shRNA 
targeting Eya2 has no effect on Eya1 protein in these cells (Figure 3.1c).  Similarly, co-
expression of an HA-tagged recombinant Eya1construct with either of two additional 
shRNAs targeting Eya1 reduces levels of HA-tagged Eya1 (Figure 3.1d).  These data 
show that shRNAs targeting Eya1 mRNA successfully reduce Eya1 protein levels.   
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Figure 3. 1 Eya1 and Smo shRNAs successfully knock-down their targets 
 
Figure 3.1 Eya1 and Smo shRNAs successfully knock-down their targets.  A) 
Three shRNAs targeting Eya1 (Eya1-1, Eya1-2, Eya1-3) successfully knock-down 
Eya1 in SL2 cells, normalized to GAPD levels and an shRNA targeting LacZ (N=7-
10).  B) Two shRNAs targeting Smo (Smo-1, Smo-2) successfully knock-down Smo in 
Sl2 cells normalized to GAPD levels and an shRNA targeting LacZ (N=2-4).  Z-test; 
*p<0.01; error bars = SEM.  C) shRNA targeting Eya1 (Eya1-1) reduces levels of 
overexpressed Eya1 when co-transfected in 293T cells; an shRNA targeting Eya2 
(Eya2) does not lower levels of Eya1 protein.  D) Two additional shRNAs targeting 
Eya1 (Eya1-2, Eya1-3) reduce levels of recombinant HA-tagged Eya1 when co-
transfected in 293T cells.  
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Having verified Eya1 shRNAs knock-down their target, we confirmed our 
preliminary RNAi screen results using lentivirus generated in our lab.  We measured the 
effect of shRNAs targeting Eya1 in SL2 cells after stimulation with SAG using multiple 
read-outs for Hh pathway activation.   
In agreement with our screening results, we found Eya1 shRNAs have the ability 
to block SAG induction of Gli-responsive F luciferase in SL2 cells normalized to R 
luciferase (Figure 3.2a).  Because the F/R luciferase signal is an artificial reporter of Hh 
pathway activation, we next looked at the induction of endogenous Gli1 gene expression 
in SL2 cells following Smo or Eya1 knock-down at the mRNA and protein levels.  We 
found the induction of SAG-induced Gli1 gene expression is blocked by shRNAs 
targeting Eya1 as measured by qRT-PCR and by western blot (Figure 3.2b-d).  The 
induction of a second Hh-response gene, Ptch1 (Goodrich et al. 1996), is also blocked by 
Smo and Eya1 shRNAs (Figure 3.2e).  Importantly, the induction of c-fos in SL2 cells by 
serum following a period of serum starvation (Johansen & Prywes 1994) is not blocked 
by shRNAs targeting Eya1 (Figure 3.2f).  Therefore, Eya1 shRNAs do not impair 
transcriptional activation generally; the effect of Eya1 shRNAs on Hh-responsive gene 
induction is specific.  
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Figure 3.2 Eya1 knock-down blocks Hh-responsive gene induction.  Fold 
stimulation by SAG (SAG/veh).  A) shRNAs targeting Eya1 block induction of F/R 
luciferase in response to SAG, normalized to an shRNA targeting LacZ (N=2-4).  B) 
shRNAs targeting Eya1 block SAG-mediated induction of endogenous Gli1 mRNA 
by qRT-PCR, normalized to GAPD levels and an shRNA targeting LacZ (N=5).  C) 
SAG-induced increases in endogenous Gli1 protein are blocked by shRNAs targeting 
Eya1.  D) Quantification of western blots showing a decrease in Gli1 protein 
induction, normalized to actin levels and an shRNA targeting LacZ (N=7-8).  E)  
shRNAs targeting Eya1 block SAG-mediated induction of endogenous Ptch1 mRNA 
by qRT-PCR, normalized to GAPD levels and an shRNA targeting LacZ (N=5).  F)  
c-fos gene expression is induced by serum stimulation following a period of serum 
starvation.  shRNAs targeting Eya1 do not block induction of c-fos mRNA following 
serum stimulation by qRT-PCR, normalized to GAPD levels and an shRNA targeting 
LacZ (N=5).  This demonstrates Eya1 is not required for general transcriptional 
activation in SL2 cells.  Z-test, *p<0.01; error bars = SEM. 
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Figure 3.2 (continued): 
 
Figure 3. 2 Eya1 knock-down blocks SAG-mediated Gli1 induction 
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Eya1 Does Not Influence Hh Pathway Activation through H2AX 
Dephosphorylation  
Eya1 is a tyrosine phosphatase and serves as a co-transcriptional factor with other 
members of the RDGN.  To investigate the mechanism by which Eya1 regulates Hh 
signal transduction, we considered the possibilities that Eya1 modulates the pathway as a 
phosphatase and/or in concert with members of the RDGN as a co-transcription factor. 
One hypothesis explaining the requirement of Eya1 for Hh pathway stimulation is 
that Eya1 dephosphorylates a substrate in the pathway required for pathway activation.  
To test this hypothesis, we began by looking broadly for potential Eya1 substrates in SL2 
cells by assaying for proteins with a change in tyrosine phosphorylation status following 
Eya1 knock-down.  We applied shRNAs targeting Eya1 to SL2 cells and probed protein 
lysate with 4G10, an antibody that detects protein tyrosine phosphorylation.  We then 
looked for a difference in the pattern of phosphorylation by western blot to identify 
changes in protein phosphorylation status.  We observed increased phosphorylation of a 
protein around 15kDa following Eya1 knock-down (Figure 3.3a).  We hypothesized that 
this band represented the tyrosine phosphorylation H2AX a protein of that size and a 
reported Eya substrate (Krishnan et al. 2009).   
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Figure 3. 3 Eya1 dephosphorylates H2AX independently of its role regulating Hh signal transduction 
 
Figure 3.3 Eya1 dephosphorylates H2AX independently of its role regulating Hh 
signal transduction.  A) A ~15kDa protein is phosphorylated following Eya1 knock-
down as indicated by 4G10, an antibody which recognizes protein tyrosine 
phosphorylation.  B) Eya1 knock-down results in higher levels of phosphorylated 
H2AX and higher levels of total H2AX protein in SL2 cell lysate as compared to 
H2AX levels in cells treated with a negative control shRNA targeting RFP; RFP is not 
expressed in SL2 cells.  C)  H2AX dephosphorylation and total protein levels are not 
modulated by Shh pathway stimulation by SAG. 
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H2AX is phosphorylated in response to DNA double-stranded breaks at Ser-139, 
then referred to as γ-H2AX.   γ-H2AX recruits DNA repair machinery to the double-
stranded break to promote cell survival.  H2AX is constitutively phosphorylated at a 
tyrosine residue which is dephosphorylated by Eya1/3; dephosphorylation of this tyrosine 
residue by Eya1/3 following DNA double-stranded breaks promotes the DNA repair 
response and cell survival (reviewed in Dickey et al. 2008).  Using an antibody 
recognizing H2AX phosphorylation at either or both phosphorylation sites, we found 
direct evidence that knock-down of Eya1 increases H2AX phosphorylation, consistent 
with our 4G10 data and published roles of Eya1 in H2AX dephosphorylation (Figure 
3.3b).  Interestingly, an antibody recognizing total H2AX independent of phosphorylation 
or ubiquitination status indicates that Eya1 may also regulate total H2AX protein levels, 
which is, to our knowledge, a novel function of Eya1 (Figure 3.3b).  By qRT-PCR, Eya1 
shRNAs did not alter H2AX expression, indicating decreased H2AX protein is the 
consequence of post-transcriptional protein regulation (data not shown).   
While interesting, the role of Eya1 in H2AX dephosphorylation appears to be 
independent of its role as a regulator of Hh signaling.  Pathway stimulation by SAG did 
not affect the phosphorylation status of H2AX or alter the effect of Eya1 knock-down on 
H2AX phosphorylation (Figure 3.3c).  We also did not find evidence that Hh pathway 
stimulation or Eya1 knock-down alters the ubiquitination status of H2AX (data not 
shown).  These results suggest Eya1 is not regulating the Hh signaling pathway via 
H2AX.   
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We next investigated a second hypothesis that Eya1 impinges upon the Hh 
pathway by regulating gene transcription as a transcriptional co-factor, potentially in 
concert with other members of the RDGN. 
Six1, an Eya1 Co-factor, Regulates Hh Signal Transduction 
To investigate whether other members of the RDGN are required for Hh 
signaling, we obtained shRNAs targeting Six1, Six2, Six4, Six5, and Dach2 provided by 
the Broad Institute RNAi Consortium.  When co-transfected with Six1-2 or Six4-5, Eya 
and Six proteins form complexes and translocate to the nucleus to activate gene 
 transcription (Ohto et al. 1999; Zhang et al. 2004b).  Eya and Dac are thought to bind 
directly in Drosophila eye development and activate gene transcription.  We did not 
include shRNAs targeting Six3 or Six6 because these members of the Six protein family 
are not known to bind Eya proteins and serve as transcriptional co-factors.   
Before testing the effect of these shRNAs on Hh pathway activation, we first 
measured the efficiency of target knock-down by qRT- PCR.  Two shRNAs targeting 
Six1 and three shRNAs targeting Six4 showed significant knock-down of their targets 
(Figure 3.4a).  We also verified Six1 knock-down by Six1 shRNAs at the protein level 
(Figure 3.4c-d).  We were unable to detect Six2 expression in SL2 cells (data not shown).  
Given these results, we tested the effects of Six1 and Six4 shRNAs on Hh pathway 
stimulation in SL2 cells using F/R luciferase values as a readout for pathway activation.  
Six1 shRNAs, but not Six4 shRNAs, block Hh pathway induction (Figure 3.4b).  These 
results raise the possibility that Eya1 may be working with Six1 to regulate Hh signal 
transduction.   
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Figure 3. 4 Six1, an Eya1 co-factor and RDGN member blocks Hh pathway activation 
 
Figure 3.4 Six1, an Eya1 co-factor and RDGN member blocks Hh pathway 
activation.  A) shRNAs targeting Dach2 (Dach2-1, Dach2-2), Six1 (Six1-1, Six1-2), 
Six4 (Six4-1, Six4-2, Six4-3, Six4-4, Six4-5), and Six5 (Six5-1) were tested for their 
ability to knock-down their targets.  Two Six1 shRNAs (Six1-1 and Six1-2) and three 
Six4 shRNAs (Six4-1, Six4-4, Six4-5) showed significant knock-down of their targets, 
normalized to GAPD levels and an shRNA targeting LacZ (N=3-6). B) shRNAs 
targeting Six1 block fold induction F/R luciferase (SAG/veh) in SL2 cells.  shRNAs 
targeting Six4 have no effect on F/R luciferase values in response to SAG, normalized 
to GAPD levels and an shRNA targeting LacZ (N=3).  C) shRNAs targeting Six1 
reduce Six1 protein levels.  D) Western blot quantification of Six1 protein in 
unstimulated (veh) cells, normalized to actin levels and an shRNA targeting LacZ 
(N=3-6).  Z-test, *p<0.01; error bars = SEM. 
 
 
 82 
 
We next verified that Six1 shRNAs block endogenous Gli1 gene induction 
following pathway activation.  Two independent shRNAs targeting Six1 block the 
induction of Gli1 mRNA and Gli1 protein following SAG stimulation by qRT-PCR and 
western blot (Figure 3.5a-c).  Notably, Six1 knock-down and Eya1 knock-down block 
SAG-induced Gli1 induction to similar extents.  In addition, knocking down Eya1 and 
Six1 simultaneously in SL2 cells does not produce a greater effect than knocking-down 
either gene alone (data not shown).  Together, these data are consistent with a model 
whereby Eya1 works in concert with its co-factor Six1 to regulate Hh pathway activation 
in SL2 cells.   
Eya1 and Six1 Act in the Hh Signaling Pathway Between Smo and Sufu 
 Genetic epistasis experiments reveal the sequential order of elements within a 
signaling pathway from ligand reception to gene induction.  To help uncover the 
molecular mechanism by which Eya1 and Six1 regulate Hh signaling, we investigated 
where along the pathway they influence pathway activation. 
At the top of the Hh signaling pathway, Hh ligands bind Ptch1, which relieves 
inhibition of Smo, resulting in pathway activation.  As shown previously, Eya1 and Six1 
are necessary for Shh and SAG-mediated induction of the pathway.  Because SAG is a 
Smo agonist, activating the pathway downstream of Hh binding to Ptch1 and downstream 
of Ptch1 disinhibition of Smo, Eya1 and Six1 are not necessary for ligand reception or 
Smo activation and must act below the level of Smo in the pathway. 
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Figure 3. 5 Six1 regulates Hh signal transduction 
 
Figure 3.5 Six1 regulates Hh signal transduction.  A) shRNAs targeting  Six1 block 
Gli1 protein induction by SAG stimulation.  B) Western blot quantification of Gli1 
protein induction (SAG/veh), normalized to actin levels and an shRNA targeting LacZ 
(N=3-6).  C)  shRNAs targeting  Six1 block Gli1 mRNA induction (SAG/veh), 
normalized to GAPD levels and an shRNA targeting LacZ (N=4-5).  Z-test, *p<0.01; 
error bars = SEM.  
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The primary cilia is a microtubule-based organelle essential for Hh signaling and 
is needed for Smo activation in vivo (Corbit et al. 2005; reviewed in Ruat et al. 2012).  In 
cultured cells, mutations in genes important for cilia development and maintenance result 
in Hh signaling deficits (Ocbina & Anderson 2008).  In addition, previous RNAi screens 
for Hh pathway regulators have identified genes that disrupt Hh signal transduction 
through disrupting primary cilia (Evangelista et al. 2008).  For these reasons, it is 
important to test for an effect of Eya1 on cilogenesis.  Staining for γ-tubulin, which 
marks basal bodies at the base of cilia, and for acetylated-α-tubulin, which marks the 
ciliary axoneme, we conclude that Eya1
-/-
 cells along the neural tube of E10.5 embryos 
develop cilia (Figure 3.6).  Therefore, Eya1 is not necessary for cilogenesis.  
Sufu is a negative regulator of the Hh signaling pathway downstream of Smo 
activation.  Sufu can bind all three Gli transcription factors (Humke et al. 2010; Pearse et 
al. 1999) and inhibits the Hh pathway by simultaneously keeping Gli activators from the 
nucleus and promoting the formation of GliR.  Loss of Sufu is sufficient for ligand-
independent activation of the pathway (Cooper et al. 2005).  To test if Eya1 and Six1 are 
acting at or downstream of Sufu, we activated the Hh pathway by knocking-down Sufu in 
SL2 cells by RNAi.  We then asked whether Eya1 and Six1 knock-down could reduce the 
heightened pathway activation in these cells.  If Eya1 and Six1 are acting at the level of 
or downstream of Sufu, we would expect to see a decrease in elevated Gli1 expression.  
If, however, Eya1 and Six1 exert their influence on the pathway upstream of Sufu, we 
would expect to see no effect of Eya1 and Six1 shRNAs on heighted levels of Gli1 
expression.     
 85 
 
 
Figure 3. 6 Eya1
-/-
 neural tube ventricles are ciliated 
 
 
 
Figure 3.6 Eya1
-/-
 neural tube ventricles are ciliated.  E10.5 wild type and Eya1
-/-
 
neural tube stained with γ-tubulin (red) to mark basal bodies at the base of cilia and 
acetylated-α-tubulin (green) to mark ciliary axoneme.  Nuclei are marked by DAPI 
(blue).  Primary cilia project into the ventricle of the neural tube (Chamerlain et al. 
2008).  The proximity of γ-tubulin and acetylated-α-tubulin in the ventricles indicate 
the presence of primary cilia. 
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We generated a stable SL2 cell line with Sufu knock-down by infecting SL2 cells 
with lentivirus encoding Sufu shRNA and selecting for infection.  Sufu knock-down (Sufu 
KD) cells have reduced Sufu protein levels (Figure 3.7a).  As expected, Sufu KD cells 
demonstrate elevated basal levels of Hh pathway activation indicated by increased levels 
of Gli1 protein in the absence of Shh or SAG stimulation (Figure 3.7a, lanes 1 and 5).  
Upon SAG stimulation, levels of Gli1 are increased further (Figure 3.7b, lanes 1 and 2). 
Eya1 and Six1 shRNAs fail to reduce elevated basal levels of Gli1 in unstimulated 
cells by western blot and qRT-PCR, demonstrating that Eya1 and Six1 are not required 
for pathway activation downstream of Sufu (Figure 3.7c-d).  However, Eya1 is still 
required for SAG-dependent pathway activation (Figure 3.7b).  These data strongly 
suggest that Eya1 and Six1 function upstream or at the level of Sufu to regulate Hh 
signaling activity. 
 87 
 
 
Figure 3. 7 Eya1 and Six1 act in the Hh signaling pathway upstream of Sufu 
 
Figure 3.7 Eya1 and Six1 act in the Hh signaling pathway upstream of Sufu.  A) 
Stable cell lines with Sufu knock-down (Sufu KD) or Gli2 overexpression (Gli2-TP) 
have elevated levels of Gli1 protein in unstimulated (veh) cells relative to veh cells 
stably overexpressing GFP (GFP-TP; see lanes 1, 3, 5).  Sufu KD cells have lower 
levels of Sufu protein.  B) Eya1 and Six1 shRNAs block SAG-dependent Gli1 
induction in Sufu KD cells.  C) In Sufu KD cells (veh), Eya1 and Six1 shRNAs do not 
reduce heightened Gli1 protein levels.  D) Eya1 and Six1 shRNAs do not reduce 
heighted basal Gli1 mRNA in Sufu KD cells relative to GFP-TP cells by qRT-PCR, 
normalized to GAPD levels and an shRNA targeting LacZ in the GFP-TP cell line 
(N=1-5).  By Student’s t-test, there is no significant (n.s.) difference in Gli1 
expression among the knock-down conditions of the Sufu KD cell line; error bars = 
SEM. 
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Gli2 is the primary transcriptional activator mediating the output of Hh signaling 
and Gli2 overexpression is sufficient for ligand-independent activation of the pathway 
(Grachtchouk et al. 2000).  To check if Eya1 and Six1 are necessary for Gli2-mediated 
gene transcription in response to Hh pathway stimulation, we asked whether Eya1 and 
Six1 knock-down block pathway activation in cells with Gli2 overexpression.   
To test this, we generated stable cell lines overexpressing Gli2 or GFP by 
transfecting SL2 cells with transposons carrying Gli2 and GFP (Gli2 TP cells) or GFP 
alone (GFP TP).  Gli2 TP and GFP TP cells express GFP, confirming TP are present 
(Figure 3.8a).  Gli2 TP cells also have elevated levels of Gli2 protein (Figure 3.8a).  
Importantly, Gli2 TP cells show elevated basal levels of Gli1 as compared to cells 
overexpressing GFP alone (Figure 3.7a, lanes 1 and 3).  Eya1 and Six1 shRNAs do not 
reduce the increased basal levels of Gli1 by western blot or qRT-PCR (Figure 3.8b-c).  
These data show that Eya1 and Six1 function upstream of Gli2 activity to regulate Hh 
signaling activity, consistent with our model that Eya1 and Six1 impact Hh signaling 
between Smo and Sufu. 
As Eya1 and Six1 are co-transcriptional activators, we felt it was important to test 
whether they function as part of a bigger transcriptional complex with Gli1 or Gli2.  
While we were able to replicate previous reports of Eya1 and Six1 forming a complex in 
vitro, co-transfecting Eya1 and Six1 constructs alone or together with either Gli1 or Gli2 
constructs failed to demonstrate binding between Eya1/Six1 and Gli transcription factors 
in 293T cells (data not shown).     
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Figure 3. 8 Eya1 and Six1 act in the Hh signaling pathway upstream of Gli2A 
 
Figure 3.8 Eya1 and Six1 act in the Hh signaling pathway upstream of Gli2A.  A) 
Gli2-TP cells overexpress Gli2; GFP-TP and Gli2-TP cells express GFP.  B) Eya1 and 
Six1 shRNA do not reduce heightened Gli1 protein levels in unstimulated (veh) Gli2-
TP cells.  C)  shRNAs targeting Eya1 or Six1 do not reduce heighted Gli1 mRNA in 
Gli2-TP cells relative to GFP-TP cells by qRT-PCR, normalized to GAPD levels and 
an shRNA targeting LacZ in the GFP-TP cell line (N=1-5).  By Student’s t-test, there 
is no significant (n.s.) difference in Gli1 expression among the knock-down conditions 
in the Gli2-TP cell line; error bars = SEM. 
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Eya1 is not Required for SAG-Induced Gli3R Inhibition  
In the absence of Hh stimulation, full-length Gli3 is proteolytically processed into 
an 83kDa amino terminal fragment, Gli3R, which is the primary transcriptional repressor 
of the pathway (Wang et al. 2000).  Hh stimulation is important to promote Gli2-
mediated gene activation as well as to inhibit Gli3R-mediated gene repression.  Eya1 is 
required for Shh and SAG-induced GliA activity.  To investigate whether Eya1 is 
necessary for SAG-induced inhibition of Gli3R, we examined Gli3 processing after Eya1 
knock-down in SL2 cells.   
As expected, knock-down of Smo prevents the ability of SAG to inhibit Gli3R 
formation.  Interestingly, we find SAG is able to inhibit Gli3R formation following Eya1 
knock-down (Figure 3.9a-b).  These data suggest that Eya1 is required specifically for 
GliA function and not for the inhibition of Gli3R formation.  A similar dissociation 
between Gli2 and Gli3 regulation was also observed after knock-down of Nrp1 and Nrp2 
(Hillman 2010) and has been reported in Arl13b mutants (Caspary et al. 2007).  As much 
is still unknown about Gli transcription factor regulation, the discovery of factors that 
uncouple their regulation may provide valuable mechanistic insight. 
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Figure 3. 9 Eya1 is not required for SAG-mediated Gli3R inhibition 
 
Figure 3.9 Eya1 is not required for SAG-mediated Gli3R inhibition.  A) SAG 
stimulation inhibits Gli3R formation.  Smo knock-down blocks the inhibition of Gli3R 
formation whereas Eya1 knock-down does not.  B) Western blot quantification of 
Gli3R, normalized to actin levels and an shRNA targeting LacZ in the unstimulated 
(veh) condition (N=3).  Z-test, *p<0.01, error bars = SEM. 
 
 92 
 
Eya1 and Six1 Regulate Positive Regulators of Hh Signaling, Nrp1 and Nrp2 
There are very few known factors acting in the Hh signaling pathway between 
Smo and Sufu.  Nrp1 and Nrp2, however, are reported positive regulators of Hh signaling 
downstream of Smo and upstream of Sufu (Hillman et al. 2011).  Additionally, in 
agreement with our data, Nrp1 and Nrp2 appear to be necessary for GliA activity but not 
for the inhibition of Gli3R formation (Hillman 2010).   
Given the similarity between these data and our own, we hypothesized that Eya1 
and Six1 regulate Hh signaling through regulating Nrp expression.  In fact, we find 
knock-down of Eya1 and Six1 result in reduced Nrp1 and Nrp2 expression by western 
blot and qRT-PCR (Figure 3.10).  These data suggest Eya1 and Six1 regulate Hh 
signaling at least partially through the regulation Nrp1 and Nrp2 expression.   
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Figure 3.10 Eya1 and Six1 regulate Nrp expression.  A) shRNAs targeting Eya1 
and Six1 reduce Nrp1 and Nrp2 protein levels.  B) Western blot quantification of Nrp1 
in unstimulated (veh) conditions; normalized to actin levels and an shRNA targeting 
LacZ (N=1 or 4).  C) Western blot quantification of Nrp2 in unstimulated (veh) 
conditions; normalized to actin levels and an shRNA targeting LacZ (N=3).  D) 
shRNAs targeting Eya1 and Six1 reduce Nrp1 mRNA, normalized to GAPD levels 
and an shRNA targeting LacZ (N=3-6).  E) shRNAs targeting Eya1 and Six1 reduce 
Nrp2 mRNA, normalized to GAPD levels and an shRNA targeting LacZ (N=2-5).  Z-
test, *p<0.01; error bars = SEM. 
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Figure 3.10 (continued): 
 
Figure 3. 10 Eya1 and Six1 regulate Nrp expression 
 95 
 
Eya1 May Contribute to MB Cell Growth 
Eya1 is specifically up-regulated in the subtype of human MB that requires Shh 
signaling for survival (Kool et al. 2008; Northcott et al. 2011; Thompson et al. 2006).  
Given our data that Eya1 is required for maximal Hh signaling activation in SL2 cells, we 
asked whether Eya1 might also be required for survival in MB cells.  Our lab has 
generated MB cell lines which retain Hh dependence in vitro (unpublished data).  These 
cells are derived from the MB tumors of Ptch1
+/-
 mice and are sensitive to Smo 
inhibitors, showing a decrease in Hh pathway activity shortly before dying (data not 
shown).  Using this cell line, we measured the effect of Smo and Eya1 shRNA on cell 
survival using an MTS assay, a measure of cellular metabolic activity which reflects the 
number of viable cells in a 96-well dish.  These MTS assays provide evidence that Smo 
shRNA and Eya1 shRNA significantly decrease the number of viable cells as compared 
to LacZ shRNA (Figure 3.11a).  Strikingly, the effect on cell survival of a shRNA 
targeting Eya1 is similar to that of Smo knock-down.  
Several cellular mechanisms regulate cell death and survival and it is possible that 
Eya1 is necessary for MB survival through a mechanism independent of Hh signaling.  
To support our hypothesis that Eya1 knock-down kills MB cells as a result of lowering 
Hh pathway activation, we conducted qRT-PCR for Gli1 after Smo and Eya1 knock-
down.  While we did detect a decrease in Gli1 mRNA levels following Smo and Eya1 
knock-down, these decreases were not significantly different from the negative control 
(Figure 3.11b).  These preliminary data raise the intriguing possibility that Eya1 may be 
important for MB cell survival.
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Figure 3. 11 Eya1 may be important for MB cell survival 
Figure 3.11 Eya1 may be important for MB cell survival.  A) shRNAs targeting 
Eya1 reduce the number of viable MB21 cells; normalized to LacZ (N=3).  B) Smo 
and Eya1 shRNA trend toward reducing Gli1 mRNA in MB21 cells, normalized to 
GAPD levels and an shRNA targeting LacZ (N=4-5).  Z-test, *p<0.01, not significant 
(n.s.); error bars = SEM. 
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Discussion 
In this chapter we have demonstrated that Eya1 is needed for maximal response to 
Hh signaling in vitro.  We have demonstrated the importance of Eya1 using multiple 
endogenous readouts of Hh-dependent gene transcription in SL2 cells, showing Eya1 
knock-down blocks the induction of multiple Hh response genes at the mRNA level and 
blocks Gli1 protein induction.  In addition, an Eya1 co-factor, Six1 is also needed for 
maximal response to Hh signaling in vitro.  These proteins, apparently acting as co-
transcription factors, regulate the expression of Hh regulators, Nrp1 and Nrp2, providing 
a mechanism by which Eya1 and Six1 exert their effect.  According to our model, Eya1 
and Six1 knock-down reduce Nrp1 and Nrp2 levels, impairing the ability of a cell to 
respond to Hh pathway stimulation.   
Furthermore, we show Eya1 and Six1 act between Smo and Sufu within the Hh 
signaling pathway.  These results are exciting because little is known about how Smo 
activation regulates Sufu activity and newly identified components between these two 
key players in the pathway are of great interest.  Interestingly, while shRNAs targeting 
Eya1 and Six1 block SAG-induced gene induction, they do not block SAG-induced 
inhibition of Gli3R formation.  These data suggest that Eya1 and Six1 are specifically 
needed to regulate Gli activator species, presumably mediated by Gli2, but are not 
involved in regulating Gli3R formation.  This finding is notable as one of the few 
examples, along with Nrp1+2 knock-down, of a pathway perturbation that disrupts Gli-
mediated gene activation without also altering Gli-mediated gene repression.   
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Dissociation of Gli2 and Gli3 Following Pathway Activation 
Primary cilia are required for Hh signal transduction, both for the activity of Gli 
activator forms as well as for generating Gli3R.  Primary cilia depend on IFT proteins.  
As such, specific IFT protein mutants that lack cilia and are unresponsive to Hh ligands 
due to a lack of Gli transcriptional regulation (Houde et al. 2006; Huangfu et al. 2003; 
Liu et al. 2005; May et al. 2005; Tran et al. 2008).  Mutants for Arl13b, however, display 
a loss of Gli2A modulation with normal Gli3R processing, uncoupling the regulation of 
these Gli proteins (Caspary et al. 2007).  Arl13b is a small GTPase localized along the 
length of the cilia and mutants have shorter cilia.  Caspary and colleagues (2007) suggest 
a model in which the creation of “high-level activator” Gli species and the release of 
these species to the nucleus require full-length cilia whereas Gli3 processing can occur 
normally in shortened Arl13b mutant cilia.  While our data show cilia are present in 
embryonic Eya1
-/-
 neural tubes, we cannot rule out the possibility that there are subtle 
differences in cilia length or function between Eya1
-/-
 and wild type animals, which may 
account for the requirement of Eya1 for SAG-induced Gli2-mediated transcriptional 
activity but not for SAG-induced inhibition of Gli3R formation.   
While it is clear that mutations resulting in altered cilia structure can affect 
processing of Gli proteins, Gli processing also requires proteins that do not play a role in 
cilia development.  We propose a model in which Eya1 and Six1 are required specifically 
for Gli2 activation through Nrp gene regulation and hypothesize this is independent of 
ciliary structure. 
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Eya1 and MB 
Activated Hh signaling causes cancer and positive regulators of the pathway serve 
as therapeutic targets.  A subtype of MB caused by over-active Hh signaling is dependent 
on Hh signaling for survival.  Our initial findings that Eya1 shRNA induce MB cell death 
to a similar extent as Smo shRNA are very exciting.  We show MB cells are dependent on 
Eya1 for survival and present the possibility that Eya1 could serve as a new therapeutic 
target.   
One likely explanation for a weak effect on Gli1 mRNA is poor knock-down of 
target mRNA by shRNA in these cells.  Knock-down in MB cells is much less efficient in 
MB21 cells as compared to SL2 cells.  In the MB21 cells, Smo shRNA and Eya1 shRNA 
only provide around 50% knock-down compared to 87% and 79% in SL2 cells, 
respectively (data not shown).   
While published data of Eya1 up-regulation in human Shh-subtype of MB and our 
own data showing Eya1 is required for MB cell survival are promising, to pursue the role 
of Eya1 in MB, additional experiments are necessary.   
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Methods 
Lentiviral Production 
 RNAi was achieved using lentivirus-delivered shRNA.  shRNA constructs were 
provided by the Broad Institute RNAi Consortium as glycerol stocks in pLKO.1 vectors.  
Glycerol stocks were streaked on ampicillin-selective plates and a single colony was 
picked and grown in a culture of LB medium containing 50-100ug/ml ampicillin.  DNA 
was prepared from bacterial cultures and purified using an EndoFree Plasmid Purification 
kit (Qiagen).   
 293T packaging cells were plated in 6cm tissue culture plates at 1.3-1.5x10
5
 
cells/ml (x6ml per plate) in “293T Growth Medium” (DMEM, 10% FBS, 1unit/ml 
penicillin, and 1ug/ml streptomycin).  Cells were incubated for 1-2 days (37 °C, 5% 
CO2), or until ~70-90% confluent.  293T cells in 6cm dishes were transfected with a 
mixture of shRNA-pLKO.1 vector (1ug), packaging plasmid (pCMV-dR8.9; 900ng), and 
envelope plasmid (VSV-G/pMD2.G; 100ng) using Fugene6 reagent (Promega; 6ul) 
following manufacturer’s instructions.  Cells were incubated for 18-20 hours and media 
was replaced with 6ml 293T Growth Medium.  24 hours later, media was collected and 
stored at 4°C.  24 hours later, a second collection of media was added to the first 
collection.  After the final harvest, media containing virus was spun at 1250rpm for 5 
minutes to pellet any packaging cells that were collected during harvesting.  Virus was 
stored at -80°C.  When virus was produced for use with MB21 cells, virus was collected 
in MB21 growth media (DMEM/F12, 1x B27 Supplement (Gibco # 17504044), 1unit/ml 
penicillin, and 1ug/ml streptomycin and streptomycin). 
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SL2-Derived Stable Cell Lines 
 To generate stable Sufu knock-down SL2 cells, SL2 cells were infected with 
lentivirus encoding shRNA targeting Sufu.  Cells were selected for successful infection 
with 4ug/ml puromycin and were maintained in puromycin. 
 To generate SL2 cells stably overexpressing GFP and Gli2, SL2 cells were 
transfected in 10cm dishes using Fugene 6 (36ul).  Cells were transfected with mouse 
PiggyBac transposase (6ug) and transposon (3ug) encoding GFP alone or Gli2 and GFP.  
These constructs were generated by Xuesong Zhao in the Segal lab (unpublished data).  
Cells were selected for successful transfection with 4ug/ml puromycin and maintained in 
puromycin. 
 To generate SL2 cells stably overexpressing Eya1, the coding region of Eya1 and 
an HA-tagged Eya1 were cloned into a pLX303 lentiviral expression vector.  pLX303 
expressing tdTomato was provided by Xuesong Zhao (Segal Lab) as a negative control.  
Cells were infected with lentivirus encoding these expression vectors.  Cells were 
selected for successful infection with 8ug/ml blastacin and maintained in blastacin. 
 To generate SL2 cells stably overexpressing Nrp1, cells were transfected using 
Lipofectatmine LTX & Plus Reagent (Invitrogen #15338100) according to 
manufacturer’s protocol for “Transfecting Plasmid DNA into NIH3T3 Cells”.  Pinco-
mNrp1 was acquired from Addgene (#21937), deposited by Guido Serini (Valdembri et 
al. 2009). 
 
293T Co-Transfection for Eya1 Protein Knock-Down 
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 1.2x10
5
 293T cells were plated in 12-well dishes in 293T growth media.  Two 
days later, cells were 70-90% confluent and were transfected using Fugene6 (3ul) and a 
mixture of two DNA constructs: an expression plasmid (1ug) and an shRNA (1ug).  18 
hours later, the media was changed.  72 hours after transfection, cells were collected for 
protein. 
 
Quantitative Real-Time PCR (qRT-PCR) 
6x10
4
 SL2 cells were plated with virus in 12-well tissue culture plates in SL2 
growth media (DMEM, 10% calf serum, 1unit/ml penicillin, 1ug/ml streptomycin, 
0.4mg/ml G418, and 0.15mg/ml zeocin); 10-30% of the total volume/well consisted of 
media containing virus.  24 hours after plating the media containing virus was changed 
with media containing 4ug/ml puromycin to select for infection.  48 hours after selection, 
cells were ~60-90% confluent and were stimulated with 300ng SAG (Enzo Life Sciences; 
in equal parts water and DMSO) or an equal volume of veh (equal parts water and 
DMSO).  48 hours after stimulation, RNA was collected from cells using TriZOL 
Reagent (Ambion #15596) following manufacturer’s protocol for RNA Isolation.  When 
RNA was collected to test for target knock-down by shRNA, cells were not stimulated 
and were collected 3-4 days after selection or until ~100% confluent. 
Following TriZOL extraction, genomic DNA was degraded by treating RNA with 
DNase (New England Biolabs #M0303S) for 15-30min at 37°C, DNAse was inactivated 
using DNAse Inactivator and the concentration of RNA was determined using a 
NanoDrop Products Spectrophotometer.  2ug of RNA was reverse-transcribed into cDNA 
using the High Capacity cDNA Reverse Transcription Kit (Life Technologies, #4368813) 
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following manufacturer’s protocol (100ul final volume).  qRT-PCR reactions were run 
using TaqMan Universal PCR Master Mix (Applied Biosystems #4324018) with TaqMan 
Gene Expression assay PCR probes (11.25ul Master Mix, 1.25ul probe, 2.5ul cDNA in 
25ul total volume).  The PCR program: 50°C for 2 minutes, 95°C for 10 minutes, then 40 
cycles of 15 seconds at 95°C followed by one minute at 60°C.  Applied Biosystems gene 
expression assays used: Eya1 Mm00438796_m1, Smo Mm01162710_m1, Gli1 
Mm00494645_m1, Ptch1 Mm00436026_m1, Gli2 Mm01293117_m1, c-fos 
Mm00487425_m1, H2AX Mm00515990_s1, Dach2 Mm00473899_m1, Six1 
Mm00808212_m1, Six2 Mm00807058_m1, Six4 Mm00803396_m1, Six5 
Mm01305439_g1, Eya3 Mm00438810_m1, Eya4 Mm00438832_m1, Math1 
Mm01181529_s1, Gas1 Mm01700206_g1, Nrp1 Mm00435371_m1, Nrp2 
Mm00803099_m1. 
qRT-PCR experiments were run using an Eppendorf ep mastercycler realplex 
machine, which tracks the fluorescent signal of the reporter dye and reports the cycle at 
which the dye signal crosses an arbitrarily threshold, the C(T) value.  At the C(T) value, 
the PCR is in an exponential phase of amplification and the initial amount of cDNA 
bound by the reporter dye is determined by calculating 2
-C(T)
.   
Each sample was run in triplicate and triplicate values were averaged.  Each probe 
was normalized to GAPD as a control for initial total amount of cDNA.  Within each 
experiment, samples were normalized to LacZ levels (our negative control).  Normalized 
values were then averaged across experiments.  The standard error of the mean (S.E.M.) 
was also determined as a measure of variability.  Statistical significance was determined 
by using a z-test relative to one in Microsoft Office Excel. 
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Western Blot 
1.1x10
5
 SL2 cells were plated with virus in 6-well tissue culture plates in SL2 
growth media; 10-30% of the total volume/well consisted of media containing virus.  24 
hours after plating the media containing virus was changed with media containing 4ug/ml 
puromycin to select for infection.  48 hours after selection, cells were stimulated with 
300ng SAG or an equal volume of veh.  48-72 hours after stimulation, protein was 
collected from cells in modified RIPA buffer (50mM NaTris pH 7.4, 150mM NaCl, 1% 
v/v NP-40, 0.25% NaDeoxycholate, 1mM DTT, 10mM NaF, 1mM activated 
NaVanadate, 1mM PMSF, protease inhibitor cocktail).  Lysate was stored at -80°C or run 
directly in a western blot.  The protein concentration of each sample was determined 
using Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad #500-0006) and a BSA 
protein standard.  Equal amounts of protein were prepared with 10x NuPAGE sample 
reducing agent (Invitrogen #NP0004) and 4x NuPAGE Sample Buffer (Invitrogen 
#NP0007), boiled for 5 minutes, and run at 115 volts in 4-12% or 10% Novex Bis-Tris 
pre-cast gels (#NP0321BOX, NP0323BOX, NP0301BOX).  Protein was transferred to a 
membrane at 30 volts for 2-3 hours.  Membranes were blocked in TBST with 5% nonfat 
dehydrated milk for 1 hour at room temperature and incubated over-night at 4°C in 
antibodies in milk.  Membranes were washed with TBST 3x 5 minutes at room 
temperature, incubated in secondary antibody (1:5000) for 1 hour at room temperature in 
block, washed with TBST 3x 10 minutes at room temperature, and developed on film 
using an ECL western blotting substrate (GE Healthcare #RPN2106; Thermo Scientific 
#34075).  Antibodies: Eya1 (Aviva Systems Biology #ARP32434), HA (Millipore #05-
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904), Actin (Cell Signaling #4968), Gli1 (Cell Signaling #2534), Anti-Phosphotyrosine 
clone 4G10 (Millipore #05-321), H2AX (Cell Signaling #2595, #5438, #2577), Six1 
(Abcam #ab84329, #ab86028), Nrp1 (R&D Systems #AF566), Nrp2 (Cell Signaling 
#3366), Sufu (Cell Signaling #2520S), Gli2 (Aviva Systems Biology #ARP31885), GFP 
(Abcam #ab6556), Gli3 (R&D Systems #AF3690). 
For western blot quantification, film was scanned using Epson perfection V750 
pro scanner and Epson scan software.  Background-subtracted band density was 
measured in ImageJ.  Each lane was normalized to actin as a loading control for initial 
total amounts of protein.  Within each experiment, samples were normalized to LacZ 
levels (our negative control).  Normalized values were then averaged across experiments.  
Statistical significance was determined by using a z-test relative to one in Microsoft 
Office Excel. 
 
MB21 MTS Assay 
MB21 cells were maintained as neurosphere cultures in MB21 growth media.  
Neurospheres were dissociated using Accutase (Sigma Aldrich #A6964) following 
manufacturer’s protocol.  50x103 cells were plated in 96-well tissue culture plates with 
20% virus by volume.  Within the same plate, serial dilutions of MB21 cells were plated 
as a standard curve.  The next day, half the media was carefully removed and replaced 
with media containing 1ug/ml puromycin (0.5ug/ml final concentration).  4 days later (5 
days after infection), cells were assayed using CellTiter96 Aqueous One Solution Cell 
Proliferation Assay (Promega #G3580) following manufacturer’s protocol.  The standard 
curve was included to ensure that the color development was in a linear range.  Within 
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each experiment, samples were normalized to LacZ levels (our negative control).  
Normalized values were then averaged across experiments.  Statistical significance was 
determined by using a z-test relative to one in Microsoft Office Excel. 
For qRT-PCR, 1x10
6
 dissociated cells were plated in 6-well tissue culture dishes 
and virus was added the following day.  Two days after viral addition, cells were 
resuspended in media containing 0.5ug/ml puromycin.  Three days after selection (5 days 
after infection), cells were collected and RNA was isolated following the protocol 
described above for SL2 cells. 
 
Cilia staining and imagining and analysis 
 E10.5 embryos were collected in cold PBS and fixed overnight in 4% PFA in 
Sorenson’s buffer at 4°C (0.0532M Na2HPO4, 0.0133M KH2PO4, pH 7.4, DEPC 
treated).  Embryos were equilibrated serially at 4°C in 10%, 20%, and 30% sucrose in 
Sorenson’s buffer overnight or until tissue sank.  Embryos were embedded in Tissue 
Freezing Medium (Triangle Biomedical Sciences, Inc. #TFM-5) and sectioned at a 
thickness of 10uM using a Leica cryostat and collected on Fisherbrand Superfrost Plus 
Microscope Slides (Fisher Scientific #12-550-15).   
 Sections were dried at room temperature for 30-60 minutes and then blocked and 
permeabilized in a 10% NGS and 0.1% Triton-X100 in PBS for 1hour.  Tissue was 
incubated overnight at 4°C with primary antibody in blocking solution.  Rabbit (rb) anti-
γ-tubulin (1:250, Sigma Aldrich #T5192) was used to mark the basal body of the cilia and 
mouse (ms) anti-acetylated-α-tubulin (1:250, Invitrogen #322700) was used to mark the 
cilia axoneme.  After primary antibody incubation, tissue was washed 3 times for 5 
 107 
 
minutes in PBST.  Secondary antibodies (1:500, anti-ms Alexa-488 and anti-rb Alexa-
546, Invitrogen) were applied in block for one hour at room temperature. Secondary 
antibody was then removed and tissue was washed 3 times for 5 minutes in PBST.  DAPI 
(5ug/ml in PBS) was applied for 1 minute and slides were washed with PBS once for 5 
minutes.  Tissue was mounted with Immu-Mount (Thermo Scientific #9990412).   
 Sections were imaged using a Leica confocal microscope and images were 
acquired with the Leica Microsystems Application Suite (24.1 build 6384).  Images were 
processed and analyzed using ImageJ software and Adobe Photoshop. 
Author Contribution: 
I independently carried out experiments for Figures 3.1-3.5, 3.10.  Dr. Pencheng 
Zhou conducted experiments for Figure 3.6.  I independently conducted the experiments 
for Figure 3.7 and 3.8 using transposon constructs developed by Dr. Xuesong Zhao. 
Maria Pazyra Murphy ran one western blot contributing to Figure 3.9; I conducted the 
rest of the experiments for that figure.  I conducted the experiments for Figure 3.11 with 
cells developed by Dr. Tatyana Ponomaryov in collaboration with Xuesong Zhao. 
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CHAPTER 4: IN VIVO EVIDENCE FOR THE 
IMPORTANCE OF EYA1 IN HH SIGNALING 
Introduction 
In the previous chapters we demonstrate Eya1 is a positive regulator of Hh 
signaling and regulates Nrp expression.  Our finding that Eya1 is important for Shh-
dependent MB survival suggests functional relevance for Eya1 in a biological system.  
Based on these data in vitro, we next investigated a role of Eya1 in Hh signaling in vivo.  
We obtained Eya1
-/-
 mice (Xu et al. 1999) and focused our attention on the 
developing cerebellum, a region where Shh is known to be a potent mitogen in 
stimulating the proliferation of granule cell precursors (GCPs; Dahmane & Ruiz i Altaba 
1999; Wallace 1999; Wechsler-Reya & Scott 1999).  In addition, we surveyed several 
other locations where Shh and Eya1 are important for development, including the 
embryonic spinal cord, otic vesicle, and lung.  In these systems, we find Eya1
-/-
 mice 
display reduced Hh signaling in vivo, Eya1
-/-
 mice present phenotypes resembling Shh 
loss-of-function, and Eya1
-/-
 mice have reduced levels of Nrp expression.  Furthermore, 
we find there is a genetic interaction between Eya1 and Hh signaling, demonstrated using 
compound Eya1/Ptch1 heterozygous mice (Goodrich et al. 1997).  Notably the 
contribution of Eya1 to Hh signaling varies among the regions analyzed.  Together, these 
data show our in vitro results predict a role for Eya1 in Hh signaling in vivo. 
Results: 
Eya1 Contributes to Cerebellar Proliferation 
 Shh, produced by Purkinje cells of the cerebellum, has long been appreciated as a 
crucial factor stimulating GCP proliferation in the developing external granule cell layer 
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(Dahmane & Ruiz i Altaba 1999; Wallace 1999; Wechsler-Reya & Scott 1999).  When 
Hh signaling is constitutively activated in GCPs, these cells can give rise to MB (Lee et 
al. 2009; Hatton et al. 2008).  Given the significance of Eya1 in MB cell proliferation 
demonstrated in Chapter 3, we examined GCP proliferation in the E18.5 Eya1
-/-
 external 
granule cell layer.  There we find a dramatic reduction in proliferation as assessed by 
Phospho-Histone H3 (PH3) staining (Figure 4.1a-b).  This phenotype is strikingly similar 
to a loss-of-Shh phenotype and consistent with a functional importance for Eya1 in Hh 
signaling in vivo and in tumorigenesis. 
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Figure 4. 1 Eya1 contributes to E18.5 cerebellar proliferation 
 
Figure 4.1 Eya1 contributes to E18.5 cerebellar proliferation.  A) Eya1
-/-
 E18.5 
cerebella display reduced proliferation as assayed by PH3 immunohistochemistry.  
Nuclei are stained with DAPI (blue).  White arrows indicate PH3-positive cells (red).  
B) Quantification of average PH3-positive cells per cerebellum (N=24 cerebellar 
sections from three wild type mice and N=36 cerebellar sections from three litter-
matched Eya1
-/-
 mice, each pair was taken from a unique litter).  Student’s t-ttest, 
*p<0.01; error bars = SEM. 
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Eya1 and Hh Signaling Interact in Otic Vesicle Development  
Cerebellar development has many similarities to the development of the auditory 
system.  For this reason, we next investigated potential in vivo phenotypes in the Eya1
-/-
 
otic vesicle.  Additionally, expression data and phenotypic analysis in the literature 
suggest a possible interaction between Hh and Eya pathways in otic vesicle development.  
Eya1 and Six1 are expressed in Shh responsive cells in the otic vesicle (Ozaki et al. 2004; 
Zheng et al. 2003) and Eya1
-/-
, Six1
-/-
, and Shh
-/-
 mutants have similar otic vesicle 
phenotypes at E10.5 (Xu et al. 1999; Zou et al. 2006; Zheng et al. 2003; Ozaki et al. 
2004).   
By in situ hybridization, we find a reduction in Gli1 expression in Eya1
-/-
 otic 
vesicles at E10.5 (Figure 4.2a).  These data suggest loss of Eya1 results in reduced Hh 
signaling and indicate that Eya1 is required for maximal Hh signaling in vivo.   
Eya1
-/-
 otic vesicles display increased cell death by TUNEL staining (Xu et al. 
1999; Zou et al. 2006) and we find that this phenotype is present in heterozygous Eya
+/-
 
otic vesicles as well (Figure 4.2b-c).  Shh
-/-
 otic vesicles also show increased cell death 
(Bok et al. 2007).  To test for a genetic interaction, we genetically amplified the Hh 
signaling pathway in Eya
+/-
 mice by crossing them to animals heterozygous for Ptch1.  
The apoptotic phenotype observed in Eya1
+/- 
mice is reversed in Eya1
+/-
/Ptch1
+/-
 double-
heterozygote otic vesicles, further demonstrating a functional relationship and a novel 
genetic interaction between these two pathways in vivo (Figure 4.2b-c).  
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Figure 4. 2 Eya1 and Shh signaling interact in the developing otic vesicle 
 
Figure 4.2 Eya1 and Shh signaling interact in the developing otic vesicle.  4.1 
Eya1
-/-
 otic vesicles at E10.5 have reduced Gli1 expression by in situ hybridization.  
4.2 E10.5 Eya
+/-
 otic vesicles have increased apoptosis as assessed by TUNEL 
staining (green), nuclei are stained by DAPI (blue).  Genetically increasing levels of 
Shh signaling by crossing Eya
+/-
 mice to Ptch1
+/-
 mice (Eya
+/-
;Ptch1
+/-
) reverses this 
phenotype.  4.3 Quantification of average TUNEL-positive cells normalized to the 
number of nuclei per otic vesicle (N=19 otic vesicle sections from two wild type mice 
and N=19 otic vesicle sections from two litter-matched Eya1
-/-
 mice, each pair was 
taken from a unique litter).  Student’s t-test, *p<0.01; error bars = SEM. 
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Dorsal-Ventral Neural Tube Patterning Appears Normal in Eya1
-/-
 Mice 
Shh is a well established morphogen in the developing vertebrate neural tube, 
acting in a concentration-dependent manner to induce cell fate along the dorsal-ventral 
axis (Dessaud et al. 2008, Jessell 2000; Ribes & Briscoe 2009).  Continuing to survey the 
Eya1
-/-
 embryo for Shh-related phenotypes, we examined the Eya1
-/-
 neural tube at E10.5 
and found that ventral cell fates are appropriately acquired (Figure 4.3).  These data 
suggest that the role of Eya1 in Hh signaling is specialized to some, but not all, 
developmental functions of Shh signaling. 
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Figure 4. 3 Ventral cell types of the neural tube appear properly patterned in Eya
-/-
 mice at E10.5 
 
Figure 4.3 Ventral cell types of the neural tube appear properly patterned in 
Eya
-/-
 mice at E10.5.  The most ventral spinal cord progenitor domains are termed 
pMN and p3.  The pMN domain gives rise to somatic motor neurons and the p3 
domain generates V3 interneurons.  Cells in the p3 region are Nkx2.2- and Nkx6.1-
positive (both shown in red).  Cells in the pMN region are Nkx6.1- and Olig2-
positive (Olig2 shown in green).  Motor neuron identify is specified in MNR2-
psoitive domain and motor neuron precursors are Islet1-positive (both shown in red).  
These ventral domains appear to be correctly specified in Eya1
-/-
 neural tubes.  
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Eya1 Regulates Nrp1 Expression in vivo 
Eya1, Six1, Nrp1, and Nrp2 are all expressed in lung tissue during development 
and have a role in regulating branching (El-Hashash et al. 2011a; El-Hashash et al. 
2011b; Ito et al. 2000; Kagoshima et al. 2001).  To test the biological relevance of our in 
vitro finding that Eya1 regulates Nrp1 expression, we looked by western blot at Nrp1 
levels in Eya1
-/-
 mouse embryos and find reduced Nrp1 protein levels in Eya1
-/-
 lung 
tissue by western blot (Figure 4.4a-b).  These data demonstrate that Eya1 regulation of 
Nrp gene expression is generalizable and biologically relevant.  Interestingly, we find 
Gli1 protein is increased Eya1
-/-
 lung tissue, indicating Hh signaling is increased (data not 
shown).  While these data do not agree with our findings that Eya1 is a positive regulator 
of Hh signaling, they are consistent with previous reports that the Eya1
-/-
 lung resembles 
Hh gain-of-function phenotypes; this could be due to a complex network involving Fgf 
signaling in the lung (El-Hashash et al. 2011b; Bellusci et al. 1997; Chuang et al. 2003). 
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Figure 4. 4 Eya1 regulates Nrp1 expression in lung 
 
Figure 4.4 Eya1 regulates Nrp1 expression in lung.  A) Nrp1 protein levels are 
reduced in Eya1
-/-
 lung tissue at E18.5 by western blot.  B) Western blot quantification 
of Nrp1; normalized to actin and wild type tissue (N=2 lung samples from two wild 
type (wt) mice and N=2 lung samples from litter-matched Eya1
-/-
 mice, each pair was 
taken from a unique litter). Student’s t-test; *p<0.01; error bars = SEM. 
 
 117 
 
Discussion 
Examining regions of the developing mouse where Shh and Eya1 are known to be 
important factors, we identify significance for Eya1 in Hh signaling and Nrp gene 
regulation in vivo.   
Reduced proliferation in E18.5 Eya1
-/-
 cerebella and reduced Gli1 expression in 
E10.5 otic vesicles provide evidence that Eya1 is required for maximal Hh pathway 
activation in vivo.  In addition, reduced GCP proliferation is consistent with our previous 
observation that Eya1 is important for MB survival.  The similarity of the Eya1
-/-
 
cerebellar proliferative phenotype to loss-of Shh signaling phenotypes (Corrales et al. 
2004; Spassky et al. 2008) and the discovery that increased Hh signaling reverses an Eya 
loss-of-function phenotype, support an interaction between these pathways.  Finally, our 
data in the embryonic lung show Eya1 is necessary for maximal Nrp expression in vivo.   
It will be interesting to know if Eya1 regulates Hh signaling through regulating 
Nrp gene expression in the cerebellum and the otic vesicle.  In addition to regulating Nrp, 
Eya1 could be acting to regulate other genes relevant to Hh signaling.  One candidate 
gene to examine would be Atoh1, also known as Math1.  Atoh1 is necessary for Shh-
dependent proliferation in the cerebellum (Ben-Arie et al. 1997; Flora et al. 2009) a well 
as MB development (Briggs et al. 2008; Flora et al. 2009).  Atoh1 is also known to be 
regulated by Eya1 and Six1 in controlling hair cell differentiation (Ahmed et al. 2012; 
Zou et al. 2008).  
As mentioned in Chapter 3, areas in development of overlap between Nrp 
expression and Hh signaling include the spinal cord, limb bud, and yolk sac.  Future 
studies looking for Nrp and Hh related phenotypes in the limb bud and yolk sac of Eya1
-/-
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embryos would be of interest as potential sites where all three proteins could be working 
together in development.  Eya1 and Six1 are also involved in renalgenesis and 
myogenesis as evidenced by phenotypes in BOR/BO patients.  Future studies examining 
potential links between Eya1, Nrp, and Shh in these areas of development could also 
provide information about how these pathways interact as well as therapeutic insight. 
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Methods 
Mice 
The mice used in this study have been described previously.  Eya1
-/-
 mice have a 
targeted deletion in the Eya1 gene from 305bp upstream of exon 10 to 1,068bp 
downstream of exon 13 in the conserved ED domain, replaced with pkg-neo (Xu et al. 
1999).  Eya1 mice were genotyped by PCR using primers 5’CAG ATT TTC TGT CTG 
GCT CC (common forward), 5'GTC GTC TGA TGA AAC ATC ATC TAT (wild type 
reverse), and 5'AAG GGC CAG CTC ATT CCT CCC ACT (neo reverse).  These mice 
were obtained from Dr. Pin-Xian Xu, Mt Sinai School of Medicine.  Ptch
+/-
 mice were 
generated by homologous recombination whereby part of ptc exon 1 and all of exon 2 
were replaced with a lacZ and a neomycin resistant gene (Goodrich et al. 1997).  Ptch1 
mice were genotyped by PCR using a master mix of the follow primers 5'CTG CGG 
CAA GTT TTT GGT TG, 5'AGG GCT TCT CGT TGG CTA CAA G, 5'TGG GGT 
GGG ATT AGA TAA ATG CC, 5'TGT CTG TGT GTG CTC GTG AAT CAC.  This 
strain was obtained from Jackson Laboratory (strain name STOCKPtch1
tmsMps
/J; stock 
number 003081).  Mice used in this study were maintained on C57B16/J or mixed 
backgrounds.  Aging of embryos was determined by designating the morning of the day a 
vaginal plug was detected as E0.5.  Pregnant females were anesthetized with isoflurane 
before decapitation.  Embryos were dissected from pregnant females in cold PBS.   
 
Immunohistochemistry 
E18.5 embryos were decapitated for cerebellar staining.  Heads were fixed 
overnight in 4% paraformaldehyde at 4°C.  Fixed brains were dissected from the skull 
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and equilibrated sequentially in 15% and 30% sucrose overnight at 4°C.  Cryopreserved 
brains were embedded and sectioned as described in Chapter 3.  For Phospho-Histone H3 
detection, sections were dried at room temperature for 30-60 minutes, rehydrated with 
PBS twice for 5 minutes and then underwent antigen retrieval in Tris-EDTA antigen 
retrieval solution (0.005M Tris, 0.001M EDTA) then blocked and permeabilized (3% 
NGS, 5% BSA, 0.3% Triton-X100 in PBS) for 1hour.  Tissue was incubated overnight at 
4°C with antibody in (3% NGS and 0.3% Triton in PBS).  Cells in M-phase of the cell 
cycle were detected using mouse anti-Phospho-Histone H3 (Ser10; 1:250, Cell Signaling 
#9706).  Primary antibody was washed, secondary antibody was applied, and cells were 
mounted as described in Chapter 3.  Phospho-Histone H3-positive cells were detected by 
immunofluorescence on a Nikon Eclipse E800 microscope with Nikon camera using NIS 
Elements imaging software (64 bit 3.22.13 Build 730).  Positive cells were manually 
counted.  Sections were collected from three pairs of mutant and wild type animals and 
each pair was collected from a unique litter.  The average number of Phospho-Histone 
H3-positive cells per cerebellum and the standard error of the mean were calculated in 
Microsoft excel.   
E10.5 tissue for detecting spinal cord markers was prepared and stained as 
described in Chapter 3 for cilia staining.  Tissue was imaged as described for Phospho-
Histone H3 staining.  Antibodies used: Olig2 (1:10,000 gift from Dr. Chuck Stiles, Dana 
Farber Cancer Institute).  Islet1 (40.2D6-c), MNR2 (81.5C10), and Nkx2.2 (74.5A5) 
were developed by Dr. Thomas M Jessell and Susan Brenner-Morton and were obtained 
from the Developmental Studies Hybridoma Bank.  Nkx6.1 (F55A10) was developed by 
Ole D. Madsen and obtained from the Developmental Studies Hybridoma Bank.  All 
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antibodies and hybridomas from the Developmental Studies Hybridoma Banks were used 
at a concentration of 3ug/ul and were developed under the auspices of NICHD and 
maintained by the University of Iowa, Department of Biology, Iowa City, IA 42242. 
 
Terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick-end labeling 
(TUNEL) 
The detection of apoptotic cells within the otic vesicle was conducted using 
DeadEnd
TM
 Fluorometic TUNEL system staining (Progema, G3250).  E10.5 tissue was 
prepared and cryosectioned as described in Chapter 3.  TUNEL-positive cells were 
imaged using a Nikon Eclipse TI inverted microscope. To produce an image of the entire 
otic vesicle, the scanning feature of NIS elements was used to stitch a series of sequential 
images.  The percent of TUNEL-positive cells was calculated using NIS elements 
software to manually count TUNEL-positive cells and the number DAPI-stained nuclei.  
The number of TUNEL-positive cells was normalized to the number of DAPI-stained 
nuclei in each otic vesicle.  Sections were collected from two pairs of mutant and wild 
type animals and each pair was collected from a unique litter.  The average number of 
TUNEL-positive cells per otic vesicle and the standard error of the mean were calculated 
in Microsoft excel.   
 
In Situ Hybridization 
 In situ hybridization probes were linearized from DNA vectors by PCR using a 
T7 and T3 or SP6 primer and TAQ polymerase.  Antisense riboprobes were polymerized 
and labeled with digoxigenin (DIG) from 5ug of DNA.  The resulting RNA probes were 
 122 
 
treated with DNAse and purified using the RNeasy Mini Kit from Qigaen (#74014) and 
diluted in Hybridization buffer (50% formamide, 5x SSC, 0.2mg/ml yeast tRNA, 
100ug/ml Heparin, 1x Denhart’s Solution, 0.1% Tween, 0.1% Chaps, 5mM EDTA) at a 
concentration of 1-2ug/ml and stored at -20°C.  The Gli1 in situ probe was a gift from Dr. 
Clifford Tabin at Harvard Medical School, who received the probe from Dr. Alexandra 
Joyner, currently at Memorial Sloan-Kettering Cancer Center. 
Slides were dried at 30°C for 2 hours then at 50°C for 15 minutes before fixation 
with RNAse-free 4% paraformaldehyde for 20 minutes at room temperature.  Slides were 
treated with 10ug/ml proteinase K for 8-11 minutes at room temperature, fixed again in 
4% paraformaldehype for 15 minutes, treated with 0.1M RNase-free triethanolamine-HCl 
with 0.25% acetic anhydride for 10 minutes, and pre-hybridized in hybridization buffer at 
65°C for 1-4 hours.  Slides were then incubated with in situ probe overnight at 65°C.  
After hybridization, slides were washed with 2x SSC and 0.2x SSC at 65°C and with 
PBT (2mg/ml BSA, 0.1% Triton X-100, PBS).  Slides were blocked (10% heat 
inactivated lamb serum in PBT) for one hour at room temperature and incubated with 
anti-DIG antibody conjugated to alkaline phosphatase in block overnight at 4°C (1:2000, 
Roche #011093274910).  Slides were washed three times in PBT for 30 minutes at room 
temperature, treated with alkaline-phosphatase buffer twice for 5 minutes at room 
tempterature (100mM Tris pH 9.5, 50mM MgCl2, 100mM NaCl, 0.1% Tween-20), and 
developed at 37°C using BM Purple AP Substrate (Roche, #14492400) until signal was 
visible.  Slides were then washed in PBS, post-fixed with 4% paraformaldehype for more 
than 15 minutes at room temperature, and mounted using 70-100% glycerol.  Signal was 
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imaged using a Nikon Eclipse E800 microscope with Nikon camera using NIS Elements 
imaging software (64bit 3.22.13 Build 730).   
 
Western Blot 
Lung tissue was collected from E18.5 embryos and manually homogenized in 
modified RIPA buffer (50mM NaTris pH 7.4, 150mM NaCl, 1% v/v NP-40, 0.25% 
NaDeoxycholate, 1mM DTT, 10mM NaF, 1mM activated NaVanadate, 1mM PMSF, 
protease inhibitor cocktail).    Lysate was stored at -80°C or run directly in a western blot 
as described in Chapter 3.  Antibodies: Actin (Cell Signaling #4968), Nrp1 (R&D 
Systems #AF566). 
Author Contribution: 
Maria Pazyra Murphy sectioned, stained, and quantified phospho-histone H3 
staining in Figure 4.1; I acquired the images shown.  I conducted experiments shown in 
Figure 4.2; Maria Pazyra Murphy quantified TUNEL positive cells.  I independently 
carried out experiments for Figures 4.3-4.4. 
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CHAPTER 5: DISCUSSION 
 
In this study, we conducted an RNAi screen to identify novel phosphatases in the 
Hh signaling pathway.  Among the many phosphatases identified in the screen, we chose 
to focus our studies on Eya1, a tyrosine phosphatase and transcriptional co-activator, 
because it is known to be differentially regulated in a subtype of MB dependent on Hh 
signaling.  We verify that SL2 cells require Eya1 for maximal response to Hh pathway 
activation using multiple pathway readouts.   
As a phosphatase, Eya1 is best characterized for its activity dephosphorylating a 
tyrosine residue on H2AX, a histone family member known to promote DNA repair in 
response to double-stranded DNA breakages.  Before its phosphatase activity was 
recognized, however, Eya1 was being studied as a co-transcriptional factor that acts in 
cooperation with members of the RDGN in multiple developmental contexts.  To 
understand the mechanism by which Eya1 regulates Hh signal transduction, we tested the 
possibilities that Eya1 acts as a phosphatase and as a transcriptional co-activator to 
regulate Hh signaling.  We examined modulation of tyrosine phosphorylation in SL2 
cells following Eya1 knock-down and/or Hh pathway stimulation.  We also applied 
shRNAs targeting other components of the RDGN to SL2 cells to determine if other 
members of the network are required for Hh signal transduction.  While Eya1-mediated 
H2AX tyrosine dephosphorylation does not appear to be linked to Hh signaling activity, 
we found that Six1, an Eya1 co-factor from the RDGN, is specifically required for Hh 
signaling in vitro, suggesting Eya1 and Six1 are acting together to regulate Hh signal 
transduction.  In support of the significance for Six1 in Hh signaling, the Drosophila 
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homolog, So, was identified in a genome-wide RNAi screen for new components of the 
Hh signaling pathway (Nybakken et al. 2005).  
For further insight into the mechanism by which Eya1 and Six1 regulate Hh 
signaling, we conducted several experiments designed to place Eya1 and Six1 within the 
Hh signaling pathway.  Because shRNAs targeting Eya1 and Six1 block Hh 
responsiveness to direct Smo activation, we know these proteins are required downstream 
of ligand reception and Smo activation.  Furthermore, the presence of cilia in the Eya1
-/-
 
neural tube shows Eya1 is not necessary for cilia formation.  The inability of shRNAs 
targeting Eya1 or Six1 to suppress heightened levels of Gli1 mRNA and protein found in 
cells with Sufu knock-down, indicates that Eya1 and Six1 act upstream of Sufu inhibition.  
Furthermore, the inability of Eya1 and Six1 shRNAs to suppress heightened levels of 
Gli1 in cells with Gli2 overexpression, demonstrates that Eya1 and Six1 are not required 
for Gli2 transcriptional activity.  Interestingly, while Eya1 and Six1 shRNA block SAG-
induced gene activation, they do not block SAG-induced inhibition of Gli3R formation.  
These data suggest that Eya1 and Six1 are specifically needed for Smo-dependent 
regulation of GliA, presumably mediated by Gli2, but are not involved in the regulation 
of Gli3R formation.   
There are very few identified factors that function in the Hh pathway between 
Smo and Sufu.  Recently, Nrp1 and Nrp2, were identified as positive Hh regulators in the 
pathway downstream of Smo and upstream or at the level of Sufu (Hillman et al. 2011).  
Interestingly, RNAi targeting Nrp also interfered with Gli transcriptional activation 
without prohibiting Gli3R inhibition (Hillman et al. 2011).  Furthermore, a published 
ChIP-on-chip experiment showed Six1 binds directly to the promoter region for Nrp1 
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(Liu et al. 2010).  In light of these data, we hypothesized that Eya1 and Six1 regulate Hh 
signaling via the transcriptional regulation of Nrp1 and Nrp2.  Our data demonstrating a 
reduction in Nrp expression following Eya1 or Six1 knock-down in SL2 cells and a 
decrease in Nrp1 protein in Eya1
-/-
 lung in vivo both support this model. 
Finally, we present evidence identifying a role for Eya1 in Hh signaling in vivo.  
A striking reduction in granule cell proliferation in E18.5 Eya1
-/-
 cerebella and reduced 
Gli1 expression in E10.5 otic vesicles provide evidence that Eya1 is required for maximal 
Hh pathway activation in vivo.  The similarity of the Eya1
-/-
 cerebellar proliferative 
phenotype to loss-of Shh signaling phenotypes (Corrales et al. 2004; Spassky et al. 2008) 
and the discovery of a genetic interaction between Eya1 and Ptch1 mutations  in the otic 
vesicle are indicative of  a role for Eya1 in the Hh pathway.     
Where in the Hh Pathway Do Eya1 and Nrp Regulate Signaling? 
The mechanistic insights that Eya1 regulates Hh signaling between Smo and Sufu 
and is needed for transcriptional activity mediated by GliA in response to Hh signaling 
but not for the inhibitory effects of GliR, allow us to hypothesize more specifically about 
where within the Hh pathway Eya1 is necessary for signaling. 
In the absence of Hh ligand, Sufu forms a complex with Gli proteins at the base of 
the cilia where Gli proteins also interact with the motor protein Kif7.  Full-length Gli is 
hyperphosphorylated and processed to GliR or is rapidly degraded (reviewed in Ryan & 
Chiang 2012).  Upon Hh binding, three events occur to inhibit GliR formation and 
promote GliA activity: 1) Sufu, Gli, and Kif7 traffic to the tip of the cilia, 2) these three 
proteins dissociate and GliA traffics from the cilia, and 3) GliA enters the nucleus where 
it promotes transcription (reviewed in Ryan & Chiang 2012).   
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From our studies and those of Hillman et al. (2011), we know that Eya1 and Nrps 
are not required for the assembly of primary cilia and that Gli2 does not require Nrp to 
translocate to the tip of the cilia upon Hh pathway stimulation.  Once translocated to the 
cilia, full-length Gli appears to be protected from phosphorylation and GliR formation is 
therefore inhibited.  We also know that GliA does not require Eya1 to enter the nucleus 
or activate gene transcription as overexpressed Gli2 induces Gli1 following Eya1 knock-
down.  Therefore, we propose that Eya1 is necessary for the disassembly of GliA protein 
complexes in the primary cilia and/or for the trafficking of GliA from the cilia.  A 
requirement of Eya1 for either of these processes is consistent with a role for Eya1 acting 
between Smo and Sufu to promote GliA activity in response to Hh signaling without 
having a role in the regulation GliR formation.  This is also consistent with our 
observations that overexpressed Gli2 is able to induce Gli1 transcription following Eya1 
knock-down as overexpressed Gli2 does not require cilia to activate gene transcription 
(Han et al. 2009).  Future experiments examining Sufu-Gli complexes and Gli2 
trafficking before and after pathway stimulation, with and without Eya1 knock-down, 
would be of great interest to test the role of Eya1 in these processes. 
A Molecular Mechanism of Eya1 Function in Hh Signaling 
 Eya1 is known to function both as a phosphatase and as a co-transcriptional factor 
(reviewed in Tadjuidje & Hegde 2012; Jemc & Rebay 2007).  While the gene was 
included as a target in our screen for its phosphatase activity, we believe Eya1 
transcriptional activator activity is involved in regulating Hh signal transduction.  We 
propose Eya1 functions with Six1 to regulate Hh signal transduction through regulation 
of Nrp gene expression (Figure 5.1a).   
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Figure 5. 1 Molecular mechanism of Eya1 function in Hh signal transduction 
 
 
  
Figure 5.1 Molecular mechanism of Eya1 function in Hh signal transduction.  We 
propose a model wherein an Eya1-Six1 transcriptional activator complex regulates 
Nrp expression.  Dashed arrows indicate the possibility that Eya1-Six1 regulate Hh-
induced Nrp gene induction in addition to regulating basal levels of Nrp expression.  
Nrp promotes a response to Hh pathway activation.  Adapted from (Ryan & Chiang 
2012).   
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Eya1 and Six1 are well established transcriptional co-factors in a variety of 
developmental contexts (reviewed in Tadjuidje & Hegde 2012; Jemc & Rebay 2007).  
Our findings that knock-down of Eya1 and Six1 have similar effects on Gli1 induction 
suggests to us that these proteins are working together to regulate Hh-responsiveness in 
SL2 cells.  Simultaneous knock-down of Eya1 and Six1 does not enhance the effect 
blocking Gli1 induction, consistent with this model. In addition, we observe 
overexpressed Eya1 and Six1 form a complex in SL2 cells as assessed by nuclear 
translocation (data not shown).  That knock-down of Eya1 and Six1 have similar effects 
on Nrp gene induction suggests they are working together to regulate Nrp expression.  
Consistent with our model that Six1 directly regulates Nrp expression, Six1 has been 
shown to directly bind to the Nrp1 promoter region in mouse cell culture (Liu et al. 
2010).  
Of course, transcriptional activation activity of Eya1 with Six1 does not rule out 
the possibility that Eya1 is also acting as a phosphatase in regulating gene expression.  
Mutations in Eya1 that disrupt the protein’s phosphatase activity also impair the in vivo 
function and transactivation activities of Eya-Six complexes (Rayapureddi et al. 2003; 
Tootle et al. 2003; Buller et al. 2001; Mutsuddi et al. 2005).  The extent to which Eya1 
phosphatase activity influences its activity as co-transcription factor, however, remains 
unclear.   
Nrp1 expression is induced by Hh signaling and is required for maximal response 
to Hh signaling (Hillman et al. 2011).  In addition, Nrp1 overexpression increases 
maximal Hh target gene activation (Hillman et al. 2011).  Thus far, our data are 
consistent with a model wherein Eya1-Six1 regulate Hh-induced Nrp gene induction in 
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addition to regulating basal levels of Nrp expression.  Further studies will be needed to 
test this model more specifically (Figure 5.1). 
A Molecular Mechanism of Nrp Function in Hh Signaling 
In some ways, the mechanism we propose above begs the question: How does 
Nrp regulate Hh signaling?  Nrps are transmembrane proteins.  The Nrp extracellular 
domain has been shown to bind ligands and facilitate the transduction of ligand signaling 
in cooperation with a co-receptor (reviewed in Pellet-Many et al. 2008; Parker et al. 
2012).  The Nrp intracellular domain contains three critical C-terminal amino acids that 
constitute a PDZ domain-binding motif, allowing Nrps to bind to PDZ domain proteins 
such as GIPC (Cai & Reed 1999).  In addition to serving as a co-receptor in complexes 
where its partner transduces signaling, this PDZ domain-binding motif may provide a 
mechanism for Nrp to directly transduce intracellular signaling.  We consider two models 
by which Nrp may be regulating the Hh signaling pathway.  First, Nrp could be serving 
as a receptor for an extracellular signal which influences Hh signaling (Figure 5.2a).  
Second, the intracellular PDZ domain of Nrp could serve as a scaffold for cytoplasmic 
components of the Hh signaling pathway (Figure 5.2b).   
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Figure 5. 2 Molecular mechanisms of Nrp function in Hh signal transduction 
 
Figure 5.2 Molecular mechanisms of Nrp function in Hh signal transduction.  A) 
Nrps serve as a receptor for an extracellular signal that engages in cross-talk with 
active Hh signaling to promote Hh-induced gene expression.  This signaling function 
may or may not involve a Nrp co-receptor (not pictured).  B) The intracellular Nrp 
PDZ domain serves as a scaffold for cytoplasmic components of Hh signaling, such 
as Sufu, Kif7, or Gli proteins in a way to promote Hh response gene expression. 
Adapted from (Ryan & Chiang 2012).   
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The first model, that Nrp is a cell-surface receptor for an extracellular signal that 
engages in cross-talk with Hh signaling, was tested by Hillman and colleagues (2011).  
Nrps are well-characterized receptors for Sema3 ligands to promote growth cone collapse 
(Chen et al. 1997; Giger et al. 1998; Kolodkin et al. 1997) and for VEGF ligands in 
vasculogenesis (Kawasaki et al. 1999; Soker et al. 1998; Takashima et al. 2002).  Hillman 
and colleagues applied Sema3A or Sema3F to SL2 cells in combination with recombinant 
Shh ligand and, across multiple concentrations of Shh, did not observe modulation of Hh 
signaling with Sema3s (2011).  Similarly, they did not observe cross-talk between Shh 
and VEGF164 and were unable to detect expression of the Nrp co-receptor VEGF-R2 in 
NIH3T3 fibroblasts (Hillman et al. 2011).  Therefore, it is unlikely that a Sema3- or 
VEGF-mediated signal is responsible for the regulation of Hh signal transduction by 
Nrps.  Nrps are cell surface receptors that interact with multiple ligands (reviewed in 
Neufeld & Kessler 2008), however, and it is possible that Nrps bind an 
untested/unidentified ligand or convey information from cell-cell interactions that cross-
talk with Hh signaling.  PlGF may be a candidate ligand to test as it has been reported to 
signal through Nrp1 to promote MB cell survival (Snuderl et al. 2013). 
A model whereby Nrp functions as a co-receptor for Hh ligands and regulates the 
pathway by influencing the Hh receptor by Ptch1, is appealing but seems highly unlikely 
given our data presented in this study.  This model is analogous to known functions of 
Nrp as a co-receptor for Sema3 and VEGF ligands (reviewed in Pellet-Many et al. 2008; 
Parker et al. 2012).  Additionally, there is much precedent in the Hh literature for Hh-
binding proteins at the cell surface that regulate pathway activity.  Examples include the 
co-receptors Ihog/Cdo, Boi/Boc, Gas1 (reviewed in Beachy et al. 2012), and Hhip 
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(Chuang & Mcmahon 1999) and, like Nrp, many of these co-receptors are also 
transcriptionally regulated by Hh signaling (Hillman et al. 2011; reviewed in Ribes & 
Briscoe 2009).  Our data and the data presented by Hillman and colleagues (2011), 
however, clearly show the effect of Eya1, Six1, and Nrp to be downstream of Hh signal 
reception and Smo activation.  Therefore, we feel confident we can rule out this model as 
a plausible mechanism. 
A third possibility, and one we favor, is that the intracellular PDZ domain of Nrp 
serves as a scaffold to localize cytoplasmic components of the Hh signaling pathway.  
Subcellular localization is an important regulatory mechanism in Hh signaling.  Many 
core components of the pathway including Ptch1, Smo, and Gli proteins are carefully 
localized and trafficked within the cell corresponding to pathway activation (Corbit et al. 
2005; Ding et al. 1999; Humke et al. 2010; Kogerman et al. 1999; Rohatgi et al. 2007).  
Sufu and Kif7 are pathway components thought to function at least in part by regulating 
the subcellular localization of Gli proteins.  This third model postulates that Nrp could 
also be an important scaffolding protein via protein interactions with its PDZ domain.   
To test these models, Nrp structure-function experiments would be helpful.  
Chimeric Nrp1 receptors have been used to demonstrate structural features that confer 
binding to Sema3A or VEGF165 (Gu et al. 2002).  Similarly, one could test the abilities 
of full-length Nrp, Nrp mutants lacking each of the individual extracellular domains, and 
a Nrp mutant lacking the PDZ-interaction domain to regulate Hh signaling (Valdembri et 
al. 2009).  These data would provide insight into the contributions of the extracellular and 
intracellular portions of the Nrp protein to Hh signal transduction.  If extracellular 
structural elements of Nrp are required, it would suggest Nrp influences Hh signaling by 
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conveying ligand-based stimuli.  If the extracellular portions of Nrp appear dispensable 
while the intracellular portion appears important for Hh signaling, this would support a 
mechanism whereby Nrp regulates Hh signaling as a scaffold for cytoplasmic factors.   
Eya1 and Hh in Development   
Phenotypic analysis of Eya1
-/-
 embryos shows that the contribution of Eya1 to 
Shh signaling varies among developmental regions analyzed.  Among many other 
functions, Hh signaling is crucial for limb specification, cerebellar proliferation, and 
neural tube patterning.  Eya1
-/-
 embryos have normal digit specification (Xu et al. 1999) 
and we find no defect in neural tube patterning.  However there is a striking cerebellar 
proliferative defect in Eya1
-/-
 mice.  These in vivo data are consistent with our findings in 
vitro that Eya1 specifically regulates GliA in response to Shh without perturbing GliR 
inhibition.  Phenotypes of mice mutant for the Gli transcription factors have 
demonstrated that some functions of Shh are heavily dependent on Shh-induced GliA 
activity while other functions rely on Hh signaling to inhibit GliR (reviewed in Hui & 
Angers 2011).  The role of Shh in digit patterning relies more heavily on Gli3 as Gli3 
mutants exhibit polydactyly while there is no Gli2 or Gli1 mutant limb phenotype 
(reviewed in Bénazet & Zeller 2009).  Conversely, cerebellar proliferation is primarily 
stimulated through the activities of GliA as Gli2 mutants exhibit a severe proliferative 
defect while the EGL of Gli3 mutants resemble that of wild type animals (Corrales et al. 
2004).  In the spinal cord, both Gli2 and Gli3 appear to be important for patterning cell 
fate (reviewed in Hui & Angers 2011).  Our finding that Eya1
-/-
 cerebella have a 
proliferation phenotype resembling Shh loss-of-function while limb and neural tube 
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patterning remain intact suggest Eya1 is necessary for the development of regions with a 
strong reliance on GliA in response to Hh without perturbing GliR inhibition. 
Eya1, Nrp, and Hh in Cancer 
 Many human cancers have active Hh signaling and aberrant Hh signaling can 
cause cancer (reviewed in Marini et al. 2011).  Several promising small molecule 
inhibitors of Smo have been developed and are in clinical trial to treat MB and BCC 
(reviewed in Cohen 2012).  The identification of additional druggable targets in the Hh 
signaling pathway is of great interest.  GCPs are thought to be the cell of origin for MB 
(reviewed in Gilbertson & Ellison 2008).  Therefore, the ability of Hh signaling to initiate 
MB is consistent with its role stimulating the proliferation of GCPs in normal 
development (reviewed in Manoranjan et al. 2012).  Published microarray data that Eya1 
is specifically up-regulated in the Shh-subtype of MB, along with our findings that Eya1 
knock-down reduces viability in a MB cell line, and with our observation that GCP 
proliferation is greatly reduced in the developing cerebellum of the Eya1
-/-
 mutant 
embryo, suggest that targeting Eya1 may provide a novel strategy for limiting the growth 
of MB. 
Overexpression of EYA proteins has been reported in many human cancers 
(reviewed in Tadjuidje & Hegde 2012).  EYA1 overexpression has been found in Wilms’ 
tumor (Li et al. 2002) and EBV-negative gastric cancer (Matsusaka et al. 2011).  
Overexpression of EYA2 is reported in epithelial ovarian cancer (Zhang et al. 2005) and 
breast cancer (Farabaugh et al. 2012).  In these cancers, EYA2 expression correlates with 
poor prognosis.  EYA4 is overexpressed in malignant peripheral nerve sheath tumors 
(MPNST; Miller et al. 2010), colon and colorectal cancers (Kim et al. 2011; Osborn et al. 
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2006), as well as esophageal adenocarcinoma (Zou et al. 2005).  Inhibition of Eya4 
expression in MPNST cells results in necrosis, suggesting Eya4 promotes tumor cell 
survival (Miller et al. 2010).  Furthermore, Pandey et al., (2010) show that over-
expression of EYA1, EYA2, or EYA3 in breast cancer cells results in increased 
proliferation, migration, invasion, and transformation.  In vivo, silencing EYA3 
expression reduces metastasis (Pandey et al. 2010).   
The molecular mechanisms by which Eya proteins contribute to these cancers is 
unknown although Pandey et al., (2010) show that the promotion of migration, invasion, 
and transformation by overexpressed Eya requires phosphatase activity.  In addition, 
misregulation of EYA expression in cancer is often accompanied by misregulation of SIX 
and DACH gene expression, suggesting that RDGN proteins may be working together to 
promote tumorigenesis in the adult (reviewed in Tadjuidje & Hegde 2012).     
Unlike most transcription factors, Eya1 has enzymatic activity which makes it an 
attractive druggable target.  Inhibiting the phosphatase activity of Eya proteins may 
sufficiently disrupt relevant Eya transactivation activities as these functions appear to be 
linked.  Although it has traditionally been difficult to specifically inhibit phosphatases, 
Eya proteins belong to the HAD family of phosphatases, which have an uncommon 
catalytic domain.  The rare biochemical properties of Eya phosphatase activity may 
provide an opportunity to identify specific Eya phosphatase inhibitors (Krueger et al. 
2013). Recently, specific Eya2 phosphatase inhibitors have been identified (Krueger et al. 
2013; Park et al. 2012).  In addition, the uricosuric agents Benzbromarone and Benzarone 
are potent Eya inhibitors, albeit less selective (Tadjuidje et al. 2012b).  Eya1 may be a 
particularly attractive target to pursue in treating Hh-dependent tumors because, unlike 
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Smo inhibitors, inhibiting Eya1 will not perturb all Hh signaling activities in patients as 
Eya1 does not appear to be a universally potent regulator of Hh signaling.  
Nrps have also been implicated in the development and progression of human 
cancer.  Nrp expression and function correlate to tumor aggressiveness and metastasis in 
a variety of tumors (reviewed in Parker et al. 2012).  Nrp interactions with VEGF ligands 
and VEGF receptors to promote angiogenesis provide tumor cells with oxygen and 
nutrients promoting their growth.  Blocking Nrp decreases tumor angiogenesis and 
growth, particularly when combined with anti-VEGF treatments (reviewed in Bagri et al. 
2009; Koch 2012).  In addition, various Sema3s, through interactions with Nrps and 
Plexins, can either promote or inhibit tumor growth by regulating tumor angiogenesis, 
metastasis, and cell survival (reviewed in Neufeld & Kessler 2008).  
Interestingly, a recent study by Snuderl et al. (2013) reports Nrp1 is required for 
the growth and spread of MB.  They report that Nrp1 acts as a receptor for PlGF, which is 
produced by the cerebellar stroma in response to tumor-derived Shh and signals, to 
promote tumor cell survival.  It will be interesting to examine whether Nrp1 is regulated 
by Eya in this context. 
Scientists have conducted unbiased screens to identify novel factors important in 
biology for decades.  The current understanding of the Hh signaling pathway has 
certainly benefited from the results of such screens. This study contributes to this rich 
literature by identifying Eya1 as a novel factor regulating Hh pathway transduction.  In 
addition, by focusing on a phosphatase important in Shh-dependent MB, it is our hope 
that this information will also contribute to the development of novel, effective cancer 
therapies. 
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